Viscocanalostomy and Canaloplasty

Number: 0435

Policy
Applicable CPT / HCPCS / ICD-10 Codes
Background
References

Policy

Scope of Policy

This Clinical Policy Bulletin addresses viscocanalostomy and canaloplasty.

Medical Necessity

Aetna considers canaloplasty medically necessary for the treatment of primary open-angle glaucoma (POAG), including normal-tension glaucoma, and for pseudo-exfoliation glaucoma.
Experimental, Investigational, or Unproven

The following procedures are considered experimental, investigational, or unproven because the effectiveness of these approaches has not been established:
1. Ab-interno canaloplasty, alone or in combination with cataract surgery for the treatment of pigmentary glaucoma;
2. Canaloplasty for all other indications (e.g., for use in corticosteroid-induced glaucoma, glaucoma gene therapy and uveitic glaucoma);
3. Canaloplasty and trabeculotomy ab interno with the OMNI System combined with cataract surgery for the treatment of POAG;
4. Combined gonioscopy-assisted transluminal trabeculotomy (GATT) with ab interno canaloplasty (ABiC) in conjunction with phacoemulsification for the treatment of POAG;
5. Combined phacoemulsification and viscocanalostomy with Ologen implant for co-existing cataract and POAG;
6. Viscocanalostomy (including phacoviscocanalostomy) for the treatment of primary open-angle glaucoma or any other indications.

Table:
CPT Codes / HCPCS Codes / ICD-10 Codes
Code	Code Description
CPT codes covered if selection criteria are met:
66174	Transluminal dilation of aqueous outflow canal; without retention of device or stent [not covered with glaucoma gene therapy]
66175	with retention of device or stent [not covered with glaucoma gene therapy]
CPT codes not covered for indications listed in the CPB:
66170	Fistulization of sclera for glaucoma; trabeculectomy ab externo in absence of previous surgery [not covered if reported for viscocanalostomy or phacoviscocanalostomy]
ICD-10 codes covered if selection critreria are met:
H40.1110 - H40.1194	Primary open angle glaucoma
H40.1210 - H40.1294	Low-tension glaucoma
H40.1410 - H40.1494	Capsular glaucoma with pseudoexfoliation of lens
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
H40.001 -H40.10x+, H40.121+ - H40.1394, H40.151 - H42	Glaucoma
H44.511 - H44.519	Absolute glaucoma
Q15.0	Congenital glaucoma
T38.0X1A - T38.0X6S	Poisoning by, adverse effect of and underdosing of glucocorticoids and synthetic analogues [corticosteroid-induced glaucoma]
*Combined phacoemulsification and viscocanalostomy with Ologen implant*:
CPT codes not covered for indications listed in the CPB:
Viscocanalostomy with Ologen implant - no specific code:
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage [phacoemulsification and viscocanalostomy with Ologen implant]
ICD-10 codes not covered for indications listed in the CPB:
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract
E10.36	Type 1 diabetes mellitus with diabetic cataract
E11.36	Type 2 diabetes mellitus with diabetic cataract
E13.36	Other specified diabetes mellitus with diabetic cataract
H25.011 - H25.9	Age-related cataract
H26.001 - H26.9	Other cataract
H28	Cataract in diseases classified elsewhere
H40.1110 - H40.1194	Primary open angle glaucoma
Q12.0	Congenital cataract
Z98.4 - Z98.49	Cataract extraction status
*Canaloplasty and trabeculotomy ab interno with the OMNI System combined with cataract surgery*:
CPT codes not covered for indications listed in the CPB:
65820	Goniotomy
66174	Transluminal dilation of aqueous outflow canal; without retention of device or stent
Other CPT codes related to the CPB:
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; without endoscopic cyclophotocoagulation
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedure)
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation
66987	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with endoscopic cyclophotocoagulation
66988	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with endoscopic cyclophotocoagulation
HCPCS codes not covered for indications listed in the CPB:
OMNI System – no specific code
ICD-10 codes not covered for indications listed in the CPB:
H40.1110 - H40.1194	Primary open angle glaucoma
H40.1310 - H40.1394	Pigmentary glaucoma
*Combined gonioscopy-assisted transluminal trabeculotomy (GATT) with ab interno canaloplasty (ABiC) in conjunction with phacoemulsification*:
CPT codes not covered for indications listed in the CPB:
65820	Goniotomy
66174	Transluminal dilation of aqueous outflow canal; without retention of device or stent [use and combination]
Other CPT codes related to the CPB:
66850	Removal of lens material; phacofragmentation technique (mechanical or ultrasonic) (eg, phacoemulsification), with aspiration
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedure)
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation
66987	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine
66988	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with endoscopic cyclophotocoagulation
ICD-10 codes not covered for indications listed in the CPB:
H40.1110 - H40.1194	Primary open angle glaucoma

Background

Glaucoma is an irreversible group of conditions/diseases involving death of the nerve cells in front of the optic nerve. It was once thought that glaucoma was generally due to increased intra-ocular pressure (IOP); however, the condition is also found in individuals with normal or low eye pressure. Therefore, diagnosis of glaucoma does not rely on increased IOP and may be related to optic nerve damage. Glaucoma is one of the leading causes of blindness with loss of peripheral vision being a hallmark sign of glaucoma.

Medication, in the form of eye drops, pills or both, is the most common early treatment for glaucoma. There are numerous medications available for treating glaucoma; all of which must be taken regularly. If medication fails, other interventions may be recommended.

Current standard surgical treatments for glaucoma include trabeculectomy or trabeculoplasty (incisional or laser). Iridotomy, iridectomy or iridoplasty may be necessary for angle-closure glaucoma.

Viscocanalostomy is an ophthalmic surgical procedure that has been developed as an alternative to trabeculectomy. In some cases, viscocanalostomy has been used in conjunction with cataract removal via phaco-emulsification. Viscocanalostomy is similar to canaloplasty in that tissue flaps are cut in the conjunctiva and the sclera. The creation of these flaps exposes a portion of the drainage (Schlemm’s) canal into which a high-viscosity elastic gel is injected. The injected material opens and enlarges the canal to allow increased fluid flow out of the anterior chamber. The tissue flaps are then closed.

Although there are a variety of viscocanalostomy techniques, the procedure basically involves production of superficial and deep scleral flaps, excision of the deep scleral flap to create a scleral reservoir, and unroofing of Schlemm's canal. A high-viscosity viscoelastic, such as sodium hyaluronate, is used to open the canal and create a passage from a scleral reservoir to the canal. The superficial scleral flap is then sutured water tight, trapping the viscoelastic until healing takes place. However, the peer-reviewed published medical literature reveals that viscocanalostomy has only been studied in a relatively small number of patients at a few centers. There are no published peer-reviewed data on long-term outcomes of viscocanalostomized patients, and what few clinical studies have been published directly comparing viscocanalostomy with trabeculectomy show that trabeculectomy is more effective at lowering intra-ocular pressure (IOP).

Randomized controlled multi-center clinical trials directly comparing viscocanalostomy with trabeculectomy are needed before viscocanalostomy can be accepted as an established alternative to trabeculectomy. As one of the leading investigators of viscocanalostomy in North America commented: "As with all glaucoma studies, long term follow-up evaluation will be required to prove its [viscocanalostomy's] real efficacy. In addition, randomized studies which would compare viscocanalostomy and phacoemulsification with other combined glaucoma procedures are also in order" (Henahan, 1998).

In a technology assessment on non-penetrating glaucoma surgery, the American Academy of Ophthalmology (AAO, 2001) stated that non-penetrating glaucoma surgery (viscocanalostomy is one of the 2 major variations of this procedure) has the potential to reduce IOP) while minimizing the risk of post-operative relative hypotony and the complications associated with hypotony. The authors found, however, that the majority of the published literature on non-penetrating glaucoma surgery contains information from case series, which are not randomized and lack a control group. The authors concluded that randomized clinical trials (RCTs) are needed to assess these procedures and to determine their role in the clinical management of glaucoma patients.

The AAO's practice guideline on the management of primary open-angle glaucoma (2005) recognized viscocanalostomy as being a non-penetrating surgery used by some physicians as an alternative to trabeculectomy, but it stated that the precise role of non-penetrating surgeries (i.e., viscocanalostomy and non-penetrating deep sclerectomy) has yet to be determined.

Shaarawy and associates (2003) studied prospectively the success rate and complications of viscocanalostomy in patients with medically uncontrolled primary and secondary open angle glaucoma (n = 57). These investigators concluded that viscocanalostomy appears to be a promising modification of filtering surgery.

Randomized controlled clinical studies comparing viscocanalostomy with trabeculectomy in glaucomatous patients have shown that trabeculectomy is more effective in lowering IOP than viscocanalostomy. In a RCT (n = 20) comparing viscocanalostomy and trabeculectomy for the treatment of patients with open angle glaucoma, Jonescu-Cuypers et al (2001) found that trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of such patients. This is in agreement with the finding of Luke et al (2002) who examined the IOP-lowering effectiveness and the post-operative complication profile of viscocanalostomy versus trabeculectomy in a prospective randomized trial (n = 60). The authors concluded that in eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing IOP than standard filtering surgery. However, post-operative complications are less frequent after viscocanalostomy. In a prospective clinical study, Kobayashi and colleagues (2003) compared the IOP-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C in patients with bilateral primary open-angle glaucoma (n = 25). The eyes of each patient were randomly assigned to receive viscocanalostomy in 1 eye and trabeculectomy with mitomycin C in the other eye. The patients were followed-up for 12 months. These researchers reported that trabeculectomy with mitomycin C may be more effective than viscocanalostomy in lowering IOP in patients with primary open-angle glaucoma, while eyes undergoing viscocanalostomy experience a lower incidence of complications, and they stated that further investigation of more cases is needed.

In a single-masked, parallel-group, prospective, randomized 24-month trial, Carassa et al (2003) compared the effectiveness and safety of viscocanalostomy and trabeculectomy in adults with uncontrolled open-angle glaucoma (n = 50). Eyes were assigned randomly to either viscocanalostomy (group 1) or trabeculectomy (group 2) with no intraoperative anti-fibrotics in the study eye. In group 1, no further intervention was allowed, whereas trabeculectomy eyes could receive subconjunctival 5-fluorouracil (5-FU) injections or laser suture lysis after surgery. It was found that viscocanalostomy is an effective IOP-lowering procedure in adults affected by open-angle glaucoma. Trabeculectomy with post-operative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive post-operative management. The authors concluded that large, multi-center controlled studies are needed to define the role of viscocanalostomy in the surgical management of glaucoma.

An assessment prepared for the Cochrane Collaboration comparing surgical and medical management of glaucoma found no studies comparing viscocanalostomy with medical management (Burr et al, 2004). The assessment noted that although viscocanalostomy may have fewer complications than trabeculectomy, viscocanalostomy may have limited effectiveness at lowering IOP.

Guidelines from the Royal College of Ophthalmologists (2004) conclude that "[a]t the present time there is insufficient evidence from prospective studies that these operations [viscocanalostomy and deep sclerectomy] have a lower incidence of long-term complications while maintaining good IOP control to advocate their use in routine glaucoma practice."

In a prospective randomized 1-year study, Kobayashi and Kobayashi (2007) compared the IOP-lowering effect of combined viscocanalostomy and phaco-emulsification and combined trabeculectomy and phaco-emulsification with mitomycin C in eyes with primary open-angle glaucoma. A total of 40 consecutive patients (40 eyes) with primary open-angle glaucoma and cataract were enrolled in this study. Eyes were assigned randomly either to trabeculectomy with mitomycin C or to viscocanalostomy in combination with phaco-emulsification and intra-ocular lens implantation. Mean baseline IOP was 24.0 +/- 2.0 mm Hg in the viscocanalostomy group and 23.7 +/- 2.6 mm Hg in the trabeculectomy group (p = 0.7). Mean post-operative IOP was 13.7 +/- 2.2 mm Hg at 3 months, 14.8 +/- 3.3 mm Hg at 6 months, and 14.9 +/- 3.0 mm Hg at 12 months in the viscocanalostomy group and 12.1 +/- 4.0 mm Hg at 3 months, 13.8 +/- 4.7 mm Hg at 6 months, and 14.1 +/- 4.4 mm Hg at 12 months in the trabeculectomy group. There was no significant difference in the mean IOP between the groups at any time. At 12 months, 17 patients (85 %) in the viscocanalostomy group and 16 patients (80 %) in the trabeculectomy group achieved an IOP of 20 mm Hg or less without medication (p = 0.7). Complications included 2 cases (10 %) of flat/shallow anterior chamber and 4 cases (20 %) of hypotony in the trabeculectomy group, whereas intra-operative micro-perforation of Descemet's membrane occurred in 3 cases (15 %) in the viscocanalostomy group. The authors concluded that there was no significant difference in IOP reduction between viscocanalostomy and trabeculectomy with mitomycin C in combination with phaco-emulsification and intra-ocular lens implantation in patients with primary open-angle glaucoma. They also stated that future study of a large population is needed to verify these observations.

In a long-term, prospective, randomized study, Gilmour et al (2007) compared the lowering effects of viscocanalostomy and trabeculectomy without anti-metabolite on IOP. The results of this study showed that at 40-month follow-up, trabeculectomy was more likely to achieve IOP levels below 18 mm Hg than viscocanalostomy. The study enrolled 21 primary open angle glaucoma patients who underwent trabeculectomy and 22 who underwent viscocanalostomy by a single surgeon familiar with both procedures. The mean pre-operative IOP was 25 mm Hg, and the trabeculectomies were performed without anti-metabolite intra-operatively, although some patients received 5-FU in the post-operative period. The follow-up period was 4 years, and the post-operative treatment was similar in both groups.

Survival analysis suggested that patients who underwent trabeculectomy had a 42 % chance of experiencing lower IOP compared to a 21 % chance in the viscocanalostomy group at 40 months. Success was defined as IOP below 18 mm Hg, and qualified success was IOP below 18 with medications. The trabeculectomy group, however, had more complications, and interventions such as needling and 5-FU injections were needed in the early post-operative period. Although the trabeculectomy group was less likely to need glaucoma medications to control IOP in the post-operative period, IOP with medication was well-controlled in the viscocanalostomy group. Of interest, only 1 patient required gonio-puncture in the viscocanalostomy group compared to other studies in the literature where gonio-puncture was required for around 30 % of patients. It is unclear how this might have influenced the results.

The authors stated that the findings of this study confirmed previous reports that the likelihood of obtaining lower IOP over the long-term with viscocanalostomy is lower than that with a standard trabeculectomy. The re-introduction of canal based surgery in adults has generated intense interest in the glaucoma community to develop new approaches to improve filtration through the trabecular and other pathways. They noted that prospective, randomized, long-term, clinical trials will hopefully provide some insight as to which of these new procedures might be most beneficial to glaucoma patients.

More recently, a glaucoma canaloplasty (enhanced viscocanalostomy) has been introduced, which involves modification of the viscocanalostomy procedure. Canaloplasty uses viscoelastic and a specialized microcatheter (e.g., iScience Surgical Ophthalmic Microcannula, Menlo Park, CA) to forcibly open the Schlemm's canal. The procedure is intended to restore the natural drainage of fluid from the eye, thus reducing IOP in persons with glaucoma.

Canaloplasty is a surgical procedure in which tissue flaps are cut in the conjunctiva and the sclera to expose the drainage area (Schlemm’s canal). Canaloplasty attempts to open the entire drainage area surrounding the anterior chamber (360^°) instead of just a portion of it, as in viscocanalostomy below. A very small catheter is placed in the opening and used to inject the high-viscosity elastic gel into the entire drainage area forming a ring around the anterior chamber. A suture loop is left in the canal to help maintain tension and keep the canal open. The canal is expanded by the injection to promote better fluid drainage.

Similar to the viscocanalostomy, canaloplasty is completed under a scleral flap. The canal is identified then intubated with a flexible microcatheter which has a lighted tip to identify its location as it passes through the Schlemm's canal. The microcatheter also has a lumen to allow for the passage of high viscosity sodium hyaluronate for dilation of the canal. Once the cannula has passed the full length (360º through) of the Schlemm's canal, a suture is tied to the cannula and as the cannula is withdrawn the suture is tied off and left in place. The intra-canalicular suture cinches and stretches the trabecular meshwork inwards and permanently opening the Schlemm's canal. The scleral flap is tightly closed as well as the conjunctiva. Before, during and after the surgery, a special ultrasound imaging system is used to help identify the canal and the instrumentation in the canal.

An important difference between viscocanalostomy and canaloplasty is that canaloplasty aims at opening the entire length of the Schlemm's canal, not just one section of it. Canaloplasty is currently under investigation. Several trials are currently underway to further support the benefits and safety of this technique.

Although a relatively new procedure, canaloplasty seems effective in lowering IOP when used in glaucoma patients as an alternative to trabeculectomy. The choice between these procedures relates to the degree of IOP lowering required by a patient as well as the patient's risk factors for complications. Canaloplasty will likely be used most often in earlier stages of glaucoma and in patients in whom bleb infection and leakage would put them at higher risk for infection-associated blindness (endophthalmitis). This procedure may also be indicated in patients who may not need IOP-lowering to the degree that is achievable with trabeculectomy. Canaloplasty and other procedures that lower IOP without creating an aqueous filtering hole in the eye with a conjunctival bleb may have an increasing role in the surgical management of patients with glaucoma because of their potentially improved safety profile.

In an international multi-center prospective study (14 sites in Germany and in the U.S.), Lewis et al (2007) assessed the safety and effectiveness of circumferential visco-dilation and tensioning of the inner wall of Schlemm's canal (canaloplasty) for the treatment of open-angle glaucoma (OAG). Adult patients having glaucoma surgery, patients with qualifying pre-operative IOP of at least 16 mm Hg or higher and open angles were eligible. Evaluation was performed at baseline and 1 day, 1 week, and 1, 3, 6, and 12 months post-operatively. After a non-penetrating dissection technique to expose Schlemm's canal was performed, a flexible microcatheter was used to dilate the full circumference of the canal by injecting sodium hyaluronate 1.4 % during catheterization. A suture loop was placed in the canal to apply tension to the trabecular meshwork. High-resolution ultrasound imaging was used to evaluate Schlemm's canal and anterior segment angle morphology, including distension of the trabecular meshwork caused by the tensioning suture. Data analysis was performed in 2 groups: Group 1, in which patients met all inclusion criteria, and Group 2, made up of Group 1 patients who had successful suture placement. Group 1 comprised 94 patients and Group 2, 74 patients. The mean baseline IOP in Group 1 was 24.7 mm Hg +/- 4.8 (standard deviation [SD]) on a mean of 1.9 +/- 1.0 medications per patient. In Group 2 (patients with sutures), the mean IOP was 16.1 +/- 4.7 mm Hg 3 months post-operatively, 15.6 +/- 4.0 mm Hg at 6 months, and 15.3 +/- 3.8 mm Hg at 1 year. Medication use dropped to a mean of 0.6 +/- 0.9 per patient at 12 months. Suture tensioning was an apparent contributing factor in achieving surgical success. Patients with measurable trabecular meshwork distension from suture tension had a mean IOP of 15.9 +/- 5.2 mm Hg at 6 months and 14.5 +/- 3.0 mm Hg at 12 months. Surgical and post-surgical adverse events were reported in 15 of 94 patients (16 %) and included hyphema (n = 3), elevated IOP greater than 30 mm Hg (n = 3), Descemet's tear (n = 1), hypotony (n = 1), choroidal effusion (n = 1), and exposed closure suture with eyelid edema and erythema epiphora (n = 1); 4 patients were subsequently converted to trabeculectomy. The authors concluded that canaloplasty was a safe and effective procedure to reduce IOP in adult patients with OAG. The major drawbacks of this study included the lack of randomization and a control group, as well as the learning curve associated with performance of the procedure. Other limitations include the small, heterogeneous patient group, short-term follow-up, and the number of patients lost to follow-up.

Shingleton et al (2008) evaluated the safety and effectiveness of canaloplasty combined with clear corneal phaco-emulsification and posterior chamber intraocular lens (IOL) implantation in in treating OAG. This international multi-center prospective study comprised adult patients with OAG having combined glaucoma and cataract surgery. Patients with qualifying treated pre-operative IOP of at least 21 mm Hg or higher and open angles were eligible. Evaluation was performed at baseline and 1 day, 1 week, and 1, 3, 6, and 12 months post-operatively. Intra-operative and post-operative high-resolution ultrasound imaging was used to assess Schlemm canal and anterior segment angle morphology, including distension of the trabecular meshwork due to the tensioning suture. Data from 54 eyes that had combined glaucoma and cataract surgery performed by 11 surgeons at 9 study sites were analyzed for this interim analysis. The mean baseline IOP was 24.4 mm Hg +/- 6.1 (SD) with a mean of 1.5 +/- 1.0 medications per eye. In all eyes, the mean post-operative IOP was 13.6 +/- 3.8 mm Hg at 1 month, 14.2 +/- 3.6 mm Hg at 3 months, 13.0 +/- 2.9 mm Hg at 6 months, and 13.7 +/- 4.4 mm Hg at 12 months. Medication use dropped to a mean of 0.2 +/- 0.4 per patient at 12 months. Surgical complications were reported in 5 eyes (9.3 %) and included hyphema (n = 3, 5.6 %), Descemet tear (n = 1, 1.9 %), and iris prolapse (n = 1, 1.9 %). Transient IOP elevation of more than 30 mm Hg was observed in 4 eyes (7.3 %) 1 day post-operatively. The authors concluded that canaloplasty combined with clear corneal phaco-emulsification and posterior chamber IOL implantation was a safe and effective procedure to reduce IOP in adult patients with OAG.

The National Institute for Health and Clinical Excellence (NICE, 2008) stated that canaloplasty for the treatment of primary OAG should be used only in the context of research or formal prospective data collection. It noted that current evidence on the safety and effectiveness of canaloplasty is inadequate in quality and quantity. Specialist advisors to NICE considered theoretical adverse events to include anterior chamber perforation, tearing of Descemet’s membrane resulting in corneal opacification or retinal damage, intra-ocular inflammation caused by the suture, cataract formation, sustained increases in IOP, hypotony, and bleb formation or suture exposure with endophthalmitis.

In a meta-analysis, Hondur and colleagues (2008) evaluated the effectiveness of non-penetrating glaucoma surgery for OAG with respect to target IOP and severity of glaucoma. Studies encompassing only combined glaucoma and cataract surgery were excluded. Measurement of effectiveness was determined on the basis of achievement of target IOP. Data related to post-operative gonio-puncture and needling with anti-metabolite application were noted. The percentage of cases achieving less than or equal to 21 mm Hg was 48.6 % after primary deep sclerectomy (DS), 68.7 % after DS with implant, 67.1 % after DS with anti-metabolite, 51.1 % after primary viscocanalostomy, and 36.8 % after viscocanalostomy with anti-metabolite or implant. Visual field parameters were almost exclusively not available; whereas cup/disk ratio and target IOP lower than 21 mm Hg were available in very few reports. With lower set IOP targets, the rates of success varied between 35 % and 86 % for DS, and between 10 % and 67 % for viscocanalostomy. The mean follow-up of the studies were mostly in the range of 3 years. The authors concluded that non-penetrating glaucoma surgery seems to provide IOP reduction into the high teens. Its potential to achieve lower target IOPs seems to be low. They stated that longer-term studies, with data related to glaucoma severity and proper target IOPs are needed.

Mendrinos et al (2008) noted that non-penetrating glaucoma surgeries have been developed in recent years in order to improve the safety of conventional filtering procedures. The goal of non-penetrating filtering procedures is to reduce IOP by enhancing the natural aqueous outflow channels, while reducing outflow resistance located in the inner wall of the Schlemm's canal and the juxta-canalicular trabecular meshwork. In the last few years, viscocanalostomy and DS with external trabeculectomy have become the most popular non-penetrating filtering procedures. Both involve removal of a deep scleral flap, the external wall of Schlemm's canal and corneal stroma behind the anterior trabeculum and Descemet's membrane, thus creating an intra-scleral space. The aqueous humour leaves the anterior chamber through the intact trabeculo-Descemet's membrane into the scleral space, from where it will egress into different pathways. The technique is associated with a long learning curve. Published clinical trials comparing non-penetrating glaucoma surgery to full-thickness trabeculectomy have a consensus on the superior safety profile of non-penetrating glaucoma surgery but are not in agreement when it comes to efficacy, where conflicting results have been found.

Lewis and colleagues (2009) assessed 2-year post-surgical safety and efficacy of canaloplasty (circumferential viscodilation and tensioning of the inner wall of Schlemm canal) to treat OAG. This international prospective study comprised adult OAG patients having glaucoma surgery or combined glaucoma-cataract surgery. Qualifying pre-operative IOP was at least 16 mm Hg and historical IOP, at least 21 mm Hg. The full circumference of the canal was viscodilated and a trabecular tensioning suture placed with a micro-catheter. Primary outcome measures included IOP and glaucoma medication use. At 24 months, all 127 eyes (127 patients) had a mean IOP of 16.0 mm Hg +/- 4.2 and mean glaucoma medication use of 0.5 +/- 0.8 (baseline values 23.6 +/- 4.8 mm Hg and 1.9 +/- 0.8 medications). Eyes with canaloplasty alone had a mean IOP of 16.3 +/- 3.7 mm Hg and 0.6 +/- 0.8 medications (baseline values 23.2 +/- 4.0 mm Hg and 2.0 +/- 0.8 medications). Eyes with combined glaucoma-cataract surgery had a mean IOP of 13.4 +/- 4.0 mm Hg and 0.2 +/- 0.4 medications (baseline values 23.1 +/- 5.5 mm Hg and 1.7 +/- 1.0 medications). The IOP and medication use results at all time points were statistically significant versus baseline (p < 0.001). The late post-operative follow-up identified 3 patients with elevated IOP. No other serious ocular or non-ocular complications were reported. The authors concluded that canaloplasty was safe and effective in reducing IOP in adult patients with OAG. These are "interim" results of an ongoing clinical study; the clinical value of canoplasty awaits the completion and final analyses of results.

Griesbacher et al (2010) reported on a prospective study evaluating 32 consecutive eyes that had canaloplasty and at least 1 year of follow-up. The mean pre-operative IOP (with medications) of 27.3 +/- 5.6 mm Hg improved to a mean post-operative IOP (without medications) of 12.8 +/- 1.5 mm Hg at 12 months. The success rate where the IOP reached less than 21, less than 18, and less than 16 mm Hg was 93.8 % (95 % confidence interval [CI]: 0.86 to 1.0), 84.4 % (95 % CI: 0.73 to 0.98), and 74.9 % (95 % CI: 0.61 to 0.92) at 12 months, respectively.

Minckler and Hill (2009) described the rationales and initial clinical outcomes in studies to date on Glaukos iStent, iScience (canaloplasty), Solx (supra-choroidal shunt), and Trabectome, which are newly developed surgical technologies for the treatment of OAG. These new approaches to angle surgery have been demonstrated in preliminary case series to safely lower IOP in the mid-teens with far fewer complications than expected with trabeculectomy and without anti-fibrotics. Trabectome and iStent are relatively non-invasive, aim to improve access of aqueous to collector channels and do not preclude subsequent standard surgery. Canaloplasty, modified from viscocanalostomy, is thought to improve trans-trabecular flow. Solx potentially offers an adjustable aqueous outflow into the supra-choroidal space.

In a prospective and non-randomized study, Chakib and colleagues (2010) evaluated the short-term clinical results and complications of viscocanalostomy. A total of 107 consecutive eyes of 67 patients who underwent viscocanalostomy were analyzed. The surgeon conducted post-operative care. The minimal follow-up was 1 year, with a mean follow-up of 13.1 months (range of 12 to 18 months). The criteria for success were defined as IOP less than 21 mm Hg without treatment. The mean pre-operative IOP was 28.3 mm Hg while the mean post-operative IOP was 5.4 mm Hg on the first day and 10.2 mm Hg at 13 months. The rate of patients who had IOP below 21 mm Hg with or without treatment was 98 % at 13 months. The complete success rate without treatment was 80 % at 13 months. Seven cases of ocular hypotony lasting more than 1 month were noted. The authors concluded that viscocanalostomy is a promising procedure because in the short-term it provides good tonometric results in glaucomatous patients without the complications of trabeculectomy. However, it remains a technique with a learning curve.

Tian and Kaufman (2013) stated that since the inner wall of Schlemm's canal (SC) is directly in contact with the trabecular meshwork (TM) for 360 degrees and the catheter device used in canaloplasty allows viscoelastic to be injected into the entire length of SC, canaloplasty might also be used to perform SC/TM-targeted delivery of transgene vectors for glaucoma gene therapy. This hypothesized new method for transgene delivery may give the transgene access to the entire inner wall of SC and the whole juxta-canalicular region of the TM and allow the transgene to be expressed in both the TM and SC without affecting the cornea, iris and ciliary body. The authors concluded that this strategy might have a greater trabecular outflow resistance-decreasing effect than either the genetic or surgical approach alone.

Aktas et al (2014) noted that SC inner wall is adjacent to the juxta-canalicular TM over their entire circumference. These researchers attempted to transfer reporter and therapeutic genes to these outflow-modulating tissues via canaloplasty surgery in live monkeys. A standard canaloplasty surgical approach was performed in cynomolgus monkeys using flexible canaloplasty catheters, modified for monkey eyes with a 175-μm outer diameter and an LED-lighted tip. A 6-0 prolene suture was used for the exact localization of SC. Trypan blue was injected during catheter withdrawal to document catheter placement within SC and to determine ease of injecting fluid into SC. Before, during, and after the injection, the position of the catheter and the anatomic details were video-captured with an externally positioned non-contact endoscopic imaging system and 50 mHz ultrasound biomicroscopy (UBM). A 360-degree catheterization and injection of dye into SC was achieved. Suture, catheter, and trypan blue were imaged with the endoscope camera system and the catheter was also visualized with UBM. Trypan blue was seen in the SC over 5 clock hours after a 1 clock-hour insertion of the catheter. The authors concluded that a modified canaloplasty catheter device might be used for gene delivery to the SC/TM area without circumferential catheterization. Moreover, they stated that further studies comparing different delivery methods of the vector/transgene into the SC using canaloplasty are needed.

The AAO Preferred Practice Pattern on primary open angle glaucoma (AAO, 2015) states that the precise role of canaloplasty in the management of open-angle glaucoma remains to be determined. The AAO states that "The safety and efficacy of canaloplasty alone and combined with phacoemulsification was described in a nonrandomized multicenter clinical trial through 3 years of follow-up [citing Lewis, et al., 2011]. No randomized clinical trial comparing trabeculectomy and canaloplasty exists. A retrospective case series found lower postoperative IOP with trabeculectomy compared with canaloplasty [citing Ayyala et al, 2011]."

An AAO‘s clinical practice guideline on “Primary open-angle glaucoma” (AAO, 2010) as well as an AAO report on “Novel glaucoma procedures” (Francis et al, 2011) did not mention phaco-viscocanalostomy as an therapeutic option. Furthermore, in an UpToDate review on “Open-angle glaucoma: Treatment” (Jacobs, 2014), viscocanalostomy and phaco-viscocanalostomy are not mentioned as therapeutic options.

In a prospective, non-randomized case-series study, Moradian et al (2013) evaluated the safety and effectiveness of viscocanalostomy in the management of medically uncontrollable primary OAG (POAG) in a developing country. A total of 14 consecutive eyes with medically uncontrollable POAG were subjected to viscocanalostomy. The main outcome measure was success rate based on the IOP level achieved post-operatively. The procedure was considered a complete success if IOP was less than 21 mmHg without any anti-glaucoma medication. Qualified success was defined as IOP of less than 21 mmHg with anti-glaucoma medication. All patients had a regular follow-up of at least 12 months. Overall, IOP was reduced from a mean baseline value of 27.9 ± 7.3 mmHg (range of 21 to 40 mmHg) to a mean final value of 16.0 ± 2.7 mmHg (range of 13 to 22 mmHg), which was statistically highly significant (p < 0.005). The mean number of pre-operative anti-glaucoma medications was 3.0 ± 0.4 (range of 2 to 4), which was reduced significantly (p < 0.0001) to 0.3 ± 0.6 (range of 0 to 2) at the last follow-up visit. One year post-operatively, complete success was achieved in 71 % and qualified success was observed in 21.4 % of patients, summing up to an overall success rate of 92.4 %. There were no major complications in any of the patients. The authors concluded that viscocanalostomy could be performed effectively and safely for control of POAG in developing countries. Moreover, they stated that “A larger number of patients and a longer follow-up period are warranted for the further evaluation of this relatively novel procedure in developing countries. In addition, comparing the future surgical cases of the same surgeon would show the learning curve of viscocanalostomy more precisely. However, we believe that the high success rate and low complication rate in these initial 14 cases are highly encouraging to suggest popularization of non-penetrating glaucoma procedures in developing countries”.

In a Cochrane review, Eldaly and colleagues (2014) compared the effectiveness of non-penetrating trabecular surgery with conventional trabeculectomy in people with glaucoma. These investigators searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2013, Issue 8), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to September 2013), EMBASE (January 1980 to September 2013), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to September 2013), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). They did not use any date or language restrictions in the electronic searches for trials. They last searched the electronic databases on September 27, 2013. This review included relevant RCTs and quasi-RCTs on participants undergoing standard trabeculectomy for OAG compared to non-penetrating surgery, specifically viscocanalostomy or deep sclerectomy, with or without adjunctive measures. Two review authors independently reviewed the titles and abstracts of the search results. They obtained full copies of all potentially eligible studies and assessed each one according to the definitions in the “Criteria for considering studies” section of this review. They used standard methodological procedures expected by The Cochrane Collaboration. These researchers included 5 studies with a total of 311 eyes (247 participants) of which 133 eyes (participants) were quasi-randomized. A total of 160 eyes that had trabeculectomy were compared to 151 eyes that had non-penetrating glaucoma surgery (of which 101 eyes had deep sclerectomy and 50 eyes had viscocanalostomy). The CI for the odds ratio (OR) of success (defined as achieving target eye pressure without eye drops) does not exclude a beneficial effect of either deep sclerectomy or trabeculectomy (OR 0.98, 95 % CI: 0.51 to 1.88). The odds of success in viscocanalostomy participants was lower than in trabeculectomy participants (OR 0.33, 95 % CI: 0.13 to 0.81). These investigators did not combine the different types of non-penetrating surgery because there was evidence of a subgroup difference when examining total success. The OR for achieving target eye pressure with or without eye drops was imprecise and was compatible with a beneficial effect of either trabeculectomy or non-penetrating filtration surgery (NPFS) (OR 0.79, 95 % CI: 0.35 to 1.79). Operative adjuvants were used in both treatment groups; more commonly in the NPFS group compared to the trabeculectomy group, but no clear effect of their use could be determined. Although the studies were too small to provide definitive evidence regarding the relative safety of the surgical procedures, these researchers noted that there were relatively fewer complications with non-filtering surgery compared to trabeculectomy (17 % and 65 %, respectively). Cataract was more commonly reported in the trabeculectomy studies. None of the 5 trials used quality of life measure questionnaires. The methodological quality of the studies was not good. Most studies were at high risk of bias in at least one domain and for many, there was lack of certainty due to incomplete reporting. Adequate sequence generation was noted only in 1 study. Similarly, only 2 studies avoided detection bias. These investigators detected incomplete outcome data in 3 of the included studies. The authors concluded that this review provided some limited evidence that control of IOP is better with trabeculectomy than viscocanalostomy. For deep sclerectomy, they could not draw any useful conclusions. This may reflect surgical difficulties in performing non-penetrating procedures and the need for surgical experience. This review has highlighted the lack of use of quality of life outcomes and the need for higher methodological quality RCTs to address these issues. Since it is unlikely that better IOP control will be offered by NPFS, but that these techniques offer potential gains for patients in terms of quality of life, the authors felt that such a trial is likely to be of a non-inferiority design with quality of life measures.

Ghate and Wang (2015) stated that primary congenital glaucoma (PCG) manifests within the first few years of a child's life and is not associated with any other systemic or ocular abnormalities. Primary congenital glaucoma results in considerable morbidity even in developed countries. Several surgical techniques for treating this condition, and lowering the IOP associated with it, have been described. These investigators compared the safety and effectiveness of different surgical techniques for PCG. They searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2014, Issue 6), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June 2014), EMBASE (January 1980 to June 2014), (January 1982 to June 2014), PubMed (January 1946 to June 2014), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). They did not use any date or language restrictions in the electronic searches for trials. They last searched the electronic databases on June 23, 2014. These researchers included all randomized and quasi-randomized trials in which different types of surgical interventions were compared in children less than 5 years of age with PCG. The authors used standard methodological procedures specified by The Cochrane Collaboration. A total of 6 trials (4 randomized and 2 quasi-randomized) with 102 eyes in 61 children were included in this analysis. Two trials were conducted in the USA and 1 trial each in Egypt, Israel, Lebanon and Saudi Arabia. All trials included children aged younger than 1 year when diagnosed with PCG, and followed them for periods ranging from 6 months to 5 years. No 2 trials compared the same pair of surgical interventions, so these investigators did not perform any meta-analysis. One trial compared trabeculotomy versus goniotomy; a 2nd trial compared combined trabeculectomy-trabeculotomy with mitomycin C versus trabeculectomy-trabeculotomy with mitomycin C and deep sclerectomy; a 3rd trial compared combined trabeculotomy-trabeculectomy versus trabeculotomy; a 4th trial compared 1 goniotomy versus 2 goniotomies; a 5th trial compared trabeculotomy versus viscocanalostomy; and the 6th trial compared surgical goniotomy versus neodymium-YAG laser goniotomy. For IOP change and surgical success (defined by IOP achieved), none of the trials reported a difference between pairs of surgical techniques. However, due to the limited sample size for all trials (average of 10 children per trial), the evidence as to whether a particular surgical technique is effective and which surgical technique is better still remains uncertain. Adverse events, such as choroidal detachment, shallow anterior chamber and hyphema, were reported from 4 trials. None of the trials reported quality of life or economic data. These trials were neither designed nor reported well overall. Two trials were quasi-randomized trials and judged to have high risk of selection bias; 4 trials were at unclear or high risk for performance bias and detection bias; and these researchers judged 1 trial to have high risk of attrition bias due to high proportions of losses to follow-up. Due to poor study design and reporting, the reliability and applicability of evidence remain unclear. The authors concluded that no conclusions could be drawn from the trials included in this review due to paucity of data. They stated that more research is needed to determine which of the many surgeries performed for PCG are effective.

Tan and colleagues (2016) stated that childhood glaucoma is known to be one of the most challenging conditions to manage. Surgical management is more complicated than in adults because of differences in anatomy from adults along with variations in anatomy caused by congenital and developmental anomalies, wide-ranging pathogenetic mechanisms, a more aggressive healing response, and a less predictable post-operative course. Challenges in post-operative examination and management in less co-operative children and the longer life expectancies preempting the need for future surgeries and re-interventions are also contributing factors. Angle surgery is usually the 1st-line treatment in the surgical management of primary congenital glaucoma because it has a relatively good success rate with a low complication rate. After failed angle surgery or in cases of secondary pediatric glaucoma, options such as trabeculectomy, glaucoma drainage devices, or cyclodestructive procedures can be considered, depending on several factors such as the type of glaucoma, age of the patient, and the severity and prognosis of the disease. Various combinations of these techniques have also been studied, in particular combined trabeculotomy-trabeculectomy, which has been shown to be successful in patients with moderate-to-advanced disease. Newer non-penetrating techniques, such as viscocanalostomy and deep sclerectomy, have been reported in some studies with variable results. The authors concluded that further studies are needed to evaluate these newer surgical techniques, including the use of modern minimally invasive glaucoma surgeries, in this special and diverse group of young patients.

The current UpToDate review on “Open-angle glaucoma: Treatment” (Jacobs, 2016) still does not mention viscocanalostomy and phacoviscocanalostomy as therapeutic options.

Canaloplasty for the Treatment of Uveitic Glaucoma

Lommatzsch and colleagues (2016) noted that glaucoma is a common vision-threatening complication of uveitis. In a pilot study, these investigators examined the outcome of canaloplasty in patients with chronic uveitis and uncontrolled secondary glaucoma. This was a retrospective study of 12 patients with medically uncontrolled secondary glaucoma who underwent canaloplasty (14 treated eyes), with follow-up of greater than or equal to 24 months. The primary outcome measure was complete and qualified (requirement for anti-glaucomatous medication) surgical success rates, as determined by a reduction in IOP and the need for anti-glaucomatous medication. Secondary outcome measures were uveitis activity, best-corrected visual acuity (BCVA), vision-threatening complications, and secondary glaucoma surgery. Canaloplasty resulted in a significant IOP reduction, from a mean pre-operative baseline level of 27.1 ± 12.3 mmHg to a mean of 14.5 ± 4.3 mmHg (p = 0.01) at 24 months. Complete success (limit of 15 mmHg) was achieved in 6 patients and qualified success in 1 patient. However, failure was noted in 5 patients, 2 of whom required additional glaucoma surgery. Topical anti-glaucomatous medications were reduced from 2.7 ± 1.2 (mean ± SD) at baseline to 0.6 ± 1.2 at 24 months (p = 0.007). Uveitis activity did not increase after surgery; BCVA was not reduced; cataract progressed in 2 patients. The authors concluded that at 2-year follow-up, overall success rate was 58 % (IOP less than or equal to 15 with or without medication), and surgery failed in 5 eyes, 2 eyes requiring additional glaucoma surgery. No harmful complications or worsening of uveitis activity were noted. These preliminary findings from a small (n= 12 patients) pilot study need to be validated by well-designed studies.

Canaloplasty for the Treatment of Normal-Tension Glaucoma

The Academy of Ophthalmology’s Preferred Practice Pattern on “Primary open-angle glaucoma” (AAO, 2016) stated that there are benefits to lowering IOP even in persons with normal-tension glaucoma.

Viscocanalostomy / Phacoviscocanalostomy for the Treatment of Glaucoma

In a retrospective study, Qian and colleagues (2017) evaluated the long-term outcome of viscocanalostomy combined with trabeculotomy (VCT) and mitomycin C in the treatment of PCG. A total of 42 eyes of 26 patients with PCG were enrolled; IOP, corneal diameter (mm) and cup/disc (C/D) were measured before and after the surgery respectively. Follow-up period was 30 months. The mean pre-operative IOP was 30.6 ± 7.35 mm Hg. Of the 42 eyes, 2 eyes were required conversion to trabeculectomy for the absence of Schlemm's canal. Of remained 40 eyes, 38 eyes (95 %) achieved successful IOP control. The average post-operative IOP was 11.69 ± 4.18 mm Hg at 12 months. The mean reduction was 18.91 mm Hg (p < 0.0001); 18 (75 %) eyes presented a reduction in corneal diameter, and 25 (62.5 %) eyes presented a C/D ratio reversal after the surgery. There was no serious complication in any patients over the follow-up period. The authors concluded that the findings of this study demonstrated that VCT was safe and effective in controlling infantile glaucoma, and it could be an alternative choice for infantile glaucoma procedure in the future although controlled studies with large subject numbers and long follow-up period are needed.

Ho and associates (2017) evaluated the efficacy of viscocanalostomy/phacoviscocanalostomy (VC/PVC) in lowering IOP in patients with normal tension glaucoma (NTG). These investigators carried out a retrospective electronic database review of patients who underwent VC/PVC for NTG between December 2009 and November 2011 at Stanley eye unit in Abergele Hospital. Goldmann applanation tonometry (GAT) was used for all IOP measurements, which were taken at the time of listing for surgery and at 1 day, 1 week, 1 month, then 3-monthly up to 1 year, then half-yearly up to 3 years post-operatively. Statistical analysis was performed using unpaired t-test. A p value of < 0.05 was accepted as the level of significance. Operations were performed on 94 eyes from 67 patients over the study period. The mean age at the time of surgery was 76.4 years. Pre-operative IOP was 17.75 ± 2.19 mmHg (range of 12 to 21 mmHg); 3 year follow-up showed a mean IOP of 13.41 ± 2.22 mmHg (range of 8 to 18 mmHg). By year 3, a total of 17 patients needed laser gonio-puncture and 25 patients needed anti-glaucoma drops; IOP was reduced by 24.4 % at 3 years post-surgery, which was statistically significant (p < 0.0001). The authors concluded that from these findings, which showed a 24.5 % reduction in IOP at 3 years with 12 % complication rate, they proposed that a logical surgical management for NTG patients would be viscocanalostomy, thereby keeping trabeculectomy as an alternative.

The authors stated that this study had several drawbacks. First, it was a retrospective study. In addition the patients in this study were from a different population, without any control group compared to other studies. This might make interpretation of these findings with other study populations difficult. Post-operative evaluation including tonometry was not masked and therefore subject to observer bias. Second, this study did not consider analysis of phakic versus pseudophakic eyes, as study participants included only 6 phakic eyes within the VC subgroup, compared to 88 pseudophakic eyes either from previous cataract operations or as a result of combined PVC surgeries. These researchers considered the number of phakic eyes to be too low to draw any statistical conclusions with sufficient power. Third, VA was not analyzed in this study. Lastly, visual field analysis in previous papers was performed using various methods, making it difficult to directly compare the visual field analysis from this study.

Viscocanalostomy and Combined Phacoemulsification with Viscocanalostomy in the Treatment of Uveitic Glaucoma

El Salloukh and colleagues (2021) noted that uveitic glaucoma commonly leads to a more intense optic nerve damage than other types of glaucoma, resulting in glaucomatous optic nerves and visual field defects. Anterior uveitis is the most commonly associated risk factor. Surgical intervention is usually indicated when all medical treatment has failed. In a retrospective, case-series study, these investigators reported 5-year results for 16 eyes of uveitic glaucoma managed with viscocanalostomy (VC)/phaco-viscocanalostomy (PVC). All patients were managed surgically with either VC or PVC. Outcomes evaluated included IOP measurement pre-listing, on day 1, year 1 to year 5. Complete success rate was defined as achieving an IOP lower than 21 mmHg or reduced by 30 % without medications, and qualified success was achieved when IOP was lower than 21 mmHg or a reduction in IOP of 30 % with topical medical therapy ± laser gonio-puncture (LGP). If further surgeries were required to reduce IOP due to glaucoma progression, then they were classified as a failure. A total of 16 patients with uveitic glaucoma were reviewed. Complete success was observed in 75 % of patients at year 1, 50 % of patients at year 3 and 19 % of patients in year 5. Conversely, qualified success was achieved in 94 % of patients at year 1, 86 % of patients at year 3 and 75 % of patients at year 5. In the group of patients requiring further surgery, 50 % of patients had previous surgeries, including cataract surgery, trabeculectomy and viscocanalostomy. There was a mean number of 4 pre-operative drops before their primary surgery and a mean drop in eye medications of 1.1 at 5 years follow-up. Success rates were prognostically linked to lower mean number of interventions and lower percentage of previous surgeries. The authors concluded that there remains a significant paucity of information in the utilization of PVC in uveitic glaucoma. The advantage of NPGS includes the lack of entry into the anterior chamber and the avoidance of an iridectomy that may reduce intra-ocular inflammation and post-operative complications. This study showed that non-penetrating surgery was successful in treating advanced uveitic glaucoma.

The authors stated that there are several limiting factors in this study. This was a retrospective case-series study with limited sample size (n = 16 eyes) and the included eyes were heterogeneous based on type of uveitis, type of procedure and lens status. None of the subjects was on immune-modulating medication and this may have affected the success rate. Furthermore, of relevance was that these investigators only had idiopathic uveitis and Fuch’s heterechromic cyclitis (FHC) and hence a direct comparison with other studies (with different uveitic etiology) was not possible. The limited sample size, heterogeneous subjects further reduced the possibility for analytical approach to the data. In addition, these findings were of surgery in a subset of patient with mild form of uveitis and could not be generalized to other types of uveitis.

Gallardo et al (2022a) noted that between 2010 and 2019, the Hispanic demographic increased in the U.S. from 16 % to 18 %. Hispanic ethnicity accounted for 52 % of U.S. population growth over this period. By 2035, Hispanic men will be the largest POAG demographic; by 2050, Hispanics will account for 50 % of POAG. Glaucoma in the Hispanic population is more prevalent than for non-Hispanic Whites with a higher proportion undiagnosed. While the Hispanic demographic is growing there remains much to be learned regarding specific risk factors for OAG in this population and how they may differ between the Hispanic and non-Hispanic White demographics. Population differences may have an effect on response to medical or surgical therapeutics; thus, it is important to understand the safety and effectiveness of glaucoma therapeutics within this significant demographic. Available evidence on the performance of various minimally invasive glaucoma surgeries in the Hispanic population remains relatively sparse. In a single-center, single surgeon study, these investigators reported the 12-month outcomes for canaloplasty followed by trabeculotomy (OMNI Surgical System) in conjunction with cataract surgery in a Hispanic (Northern Mexico/mestizo) OAG population from El Paso (TX). A total of 39 subjects were treated and followed for 12 months (March 2019 to April 2021). Demographics aside from ethnicity were similar to those for the GEMINI study as a whole; mean age and percentage female were 68.3 years, 60 % in GEMINI and 69.2 years, 51 % in this subset. Average [SD} Visual Field Mean Deviation and Pattern Standard Deviation were −3.9 [3.5] dB and 3.2 [2.1] dB compared to −3.7 [3.6] dB and 3.7 [2.6] dB for the GEMINI study as a whole. It was noted that nearly all (39/41, 95 %) of subjects self-reporting as Hispanic in the GEMINI study were included in the present single-center analysis. Before washout, mean IOP was 16.5 (2.8) mmHg on average 2.0 (1.1) medications. Unmedicated mean (SD) DIOP was 22.8 mmHg (2.5) pre-operatively and 14.9 (3.6) at 12 months, (-7.9 mmHg, -35 %, p < 0.001). Most (38/39, 97 %) had an IOP reduction, and 85 % had 20 % or greater reduction. Medications were reduced to 0.15 (0.43, -93 %, p < 0.001). The majority (87 %) of patients needed no medications. There were no SSI; AEs were mild, self-limiting and typical of MIGS combined with cataract surgery; IOP increased 10 mmHg or more at 1 month or longer (2, 5.1 %), mild inflammation (3, 7.6 %), and hyphema 1 mm or greater (1, 2.6 %). The authors concluded that these findings were derived from a single-center, single-surgeon dataset. These researchers stated that results from other centers and confirming studies are needed; longer-term data to establish effect durability would be desirable. However, within the 12 months of follow-up, no SSI was needed; and medication re-introduction was limited to 5 of 39 patients suggesting that the therapeutic effect was not diminishing.

These investigators stated that this trial was a case-series of patients undergoing the OMNI procedure in conjunction with cataract surgery; thus, it was not possible with the current dataset to know the relative contributions of the OMNI procedure and of cataract surgery to the observed IOP lowering. However, a recent systematic review and meta-analysis of 32 studies including 1,826 patients (Armstrong et al, 2017) found that cataract surgery alone could provide a 14 % reduction in IOP at 12 months post-surgery in contrast to the 35 % reduction observed in the present study. The OMNI device is a safe, implant-free MIGS combining trabeculotomy and canaloplasty. The present analysis indicated that the favorable safety and effectiveness for OMNI reported in the broader population (Gallardo et al, 2021) was also observed in Hispanic patients.

Dickerson et al (2024) examined if there was an association between severity of glaucoma and IOP and medication (med) outcomes for patients in the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) Trial, which entailed 11 ophthalmology practices in 8 U.S. states. These investigators carried out post-hoc analysis of all eyes enrolled and treated with ab interno canaloplasty and trabeculotomy in the retrospective, multi-center ROMEO Trial. Eyes were grouped according to visual field mean deviation (MD): mild (MD better than -6 dB), moderate (MD between -6 and -12 dB), advanced (-12 dB or worse). IOP and med outcomes at 12 months were compared across groups. Least squares regression was used to examine the relationship of MD with month-12 IOP. Outcomes for 1st and last MD deciles were compared as a sensitivity analysis. A total of 127 eyes were available for analysis including 79 mild, 42 moderate, 6 advanced. Most eyes had a reduction in IOP at month-12 (70 %) with most at 18 mmHg or less. Percentage IOP reduction was similar across the groups (mild 16.9 %, moderate 18.6 %, and advanced 18.0 %) with mean month-12 IOP between 14 and 16 mmHg. Medications were also reduced in all 3 groups; -0.8 (mild, p < 0.001), -0.55 (moderate, p < 0.05), and -1.0 (advanced, p = 0.139, ns). Regression analysis revealed no relationship between month-12 IOP and MD. Med reductions were observed for all groups with a reduction of 1 or more medications observed in (%, 95 % CI) 69 %, 59 to 79 (mild), 50 %, 35 to 65 (moderate), and 60 %, 21 to 99 (advanced). Secondary interventions tended to have greater incidence with worse MD likely reflecting lower desired IOP targets. The authors concluded that analysis of data from the ROMEO Trial suggested that similar meaningful IOP and med reductions could be expected across the range of disease severity studied. Moreover, these researchers stated that confirmation of these findings through additional studies, with a greater representation of patients with advanced field loss, is needed to determine the role of MIGS in glaucoma patients with advanced disease.

The authors stated that this study had 2 main drawbacks. First, this was a post-hoc analysis of a retrospective study. However, the study included all available eligible patients treated with OMNI; therefore, mitigating the risk of selection bias. Also, this was a multi-center study; thus, mitigating the risk of investigator or center bias. Moreover, a retrospective study of patients treated in actual clinical practice, in the authors’ view, provided data more generalizable to the actual outcomes others may obtain with OMNI. Second, the majority of patients in this study were mild or moderate with a small number of patients having advanced visual field loss, extrapolation of these findings were therefore limited. Nevertheless, these researchers felt confident that for the range of visual field deficits included, the study conclusions were valid.

Corticosteroid-Induced Glaucoma

Brusini and colleagues (2018) presented the mid-term results of canaloplasty in a small cohort of patients with corticosteroid-induced glaucoma (CIG). A total of 9 eyes from 7 patients with various types of CIG in maximum medical therapy underwent canaloplasty. Patients underwent complete ophthalmic examination every 6 months. Success was defined as: post-operative IOP of less than or equal to 21 mmHg and less than or equal to 16 mmHg without ("complete success"), and with/without medical treatment ("qualified success"). The IOP reduction had to be greater than or equal to 20. The number of medications before and after surgery was considered. The follow-up mean period was 32.7 ± 20.8 months (range of 14 to 72 months). The pre-operative mean IOP was 30.7 ± 7.2 mmHg (range of 24 to 45). The mean IOP at 6 and 12-month follow-up was 13.1 ± 2.6 mmHg, and 13.7 ± 1.9 mmHg, respectively. Qualified and complete success at 6 and 12 months was 100 % for both of the 2 definitions. The number of medications used pre-operatively and at the 12-month follow-up was 4.3 ± 0.7, and 0.2 ± 1.0, respectively. No serious complication was observed. The authors concluded that the mid-term results of canaloplasty in patients with CIG appeared to be very promising. They stated that canaloplasty should be considered as a possible alternative to filtering surgery in this form of glaucoma, when medical therapy is not sufficient to maintain the IOP within reasonable limits. Moreover, they stated that the study is currently still underway. New patients with CIG that fit the inclusion criteria are being added and follow-up data of existing patients are being constantly updated to provide long-term results and a larger cohort for the future study. Regarding these patients, multi-centric randomized studies with a larger population, where canaloplasty is compared to gold standard surgery (trabeculectomy), are needed to draw more definite and robust conclusions.

The authors stated that even the results obtained were very promising, it should be remembered that this was a non-randomized study with a small sample of patients (n= 9 eyes) without a control group. Another drawback of this study was that both eyes of 2 patients had been considered. Even if this could be incorrect from a statistical point of view, considering the small number of patients treated, these researchers decided to describe all cases they treated with this surgical procedure.

Stegmann Canal Expander for Canaloplasty

In a non-comparative, prospective study, Grieshaber and colleagues (2017) examined longer-term post-surgical safety and efficacy of a new expander for Schlemm's canal (SC). A total of 42 White patients with medically uncontrolled POAG underwent primary canaloplasty with greater than 2-year follow-up. The bleb-independent procedure comprised catheter-assisted canaloplasty and implantation of 2 Stegmann Canal Expanders to maintain trabecular distension and canal patency over 180°; IOP, glaucoma medication use and complications were assessed. Mean IOP was 26.8 ± 5.6 mmHg pre-surgery, 12.8 ± 1.5 mmHg at 6 months, 13.2 ± 1.2 mmHg at 12 months and 13.3 ± 2.5 mmHg at 24 months (p < 0.001). Rate of complete success, defined as IOP less than or equal to 21, less than or equal to 18, and less than or equal to 16 mmHg and a ≥ 30 % IOP reduction, was 85 % (95 % CI: 0.76 to 0.95), 85 % (0.76 to 0.95) and 82 % (0.70 to 0.96) at 12 months and 83 % (0.73 to 0.94), 80 % (0.70 to 0.92) and 80 % (0.70 to 0.92) at 24 months. Pre-operative factors were not significant predictors of less than or equal to 16 mmHg IOP reduction: IOP (hazard ratio [HR]: 0.68; 95 % CI: 0.44 to 1.04; p = 0.08), mean visual defect (1.06; 0.90 to 1.20; p = 0.47), number of medications (0.59; 0.17 to 2.14; p = 0.42) and age (0.96; 0.87 to 1.13; p = 0.41). Number of medications dropped from 2.8 ± 0.4 pre-surgery to 0.2 ± 0.5 post-surgery (p < 0.001). Mean pre-operative BCVA was 0.19 ± SD 0.21 (range of 0 to 1.6), and logMAR was similar to 0.23 ± 0.16 (range of 0 to 1.6; p = 0.42) after a mean follow-up of 27.4 months. Complications included peripheral Descemet's membrane detachment (7.2 %) and trimming of the expander (4.7 %) during surgery, and transient micro-hyphema (23.8 %) and IOP elevation (7.2 %) post-surgery. The authors concluded that canaloplasty with the Stegmann Canal Expander was a safe and effective procedure to reduce IOP in White patients with moderate-to-advanced POAG; however, comparative, randomized trials are needed to draw final conclusions.

The authors stated that in spite of the promising findings, the results of this study need to be interpreted with caution due to study limitations. First, the study design was un-masked and non‐comparative; thus, it lacked a control group, namely standard canaloplasty. Second, the Stegmann Canal Expander has only been evaluated in White patients with POAG undergoing primary surgery, thus, the results could not be extrapolated to patients of other ethnicity, to eyes with other types of glaucoma, or to eyes with previous surgery, which could have impeded cannulation of SC and implantation of the device. Furthermore, it should be noted that the surgeons in this study had many years of experience with non‐penetrating glaucoma surgery, and thus, the results did not include the long learning curve related to the dissection of the scleral flaps and preparation of the Descemet's membrane window.

Grieshaber (2018) stated that the concept of canaloplasty is to increase aqueous egress through all structures that control the aqueous outflow, such as the trabecular meshwork, SC, and collector channels, by visco-modulation and by placing of a suture stent into the canal. Clinical studies showed canaloplasty to be safe and efficient in lowering the IOP; however, proper knotting of the tensioning suture is technically challenging and even impossible if circumferential cannulation cannot be achieved. Furthermore, protrusion of the suture stent is a potential lifelong risk. The specific design of the Stegmann Canal Expander allows a permanent expansion of the canal and distension of the trabecular meshwork; 2 expanders are implanted on either side of the surgically created ostium of SC to treat half of the circumferential outflow system. The author described the technique step-by-step, provided the clinician with surgical pearls, and highlighted the management of adverse events (AEs). This investigator noted that technically, implantation of the Stegmann Canal Expander was simple and did not require a long learning curve, compared to placing and knotting a tensioning suture. Most issues were related to the 2-flap dissection technique (deep sclerectomy technique) and not to implantation of the Stegmann Canal Expander; and IOP reduction without medications to the low teens could be achieved. The authors concluded that Stegmann Canal Expander is a novel micro-device that has the potential to make canaloplasty a simplified, more controlled, and reproducible surgical procedure.

Furthermore, an UpToDate review on “Open-angle glaucoma: Treatment” (Jacobs, 2019) does not mention canal expander as a management tool.

Combined Phacoemulsification and Viscocanalostomy with Ologen Implant

In a prospective, interventional, randomized clinical study, Gad and colleagues (2019) examined the efficacy of the biodegradable collagen implant Ologen as an adjuvant in phaco-viscocanalostomy in patients with co-existing cataract and POAG. This trial entailed patients with co-existing cataract and glaucoma who were randomized to receive either phaco-viscocanalostomy (Phacovisco group) (39 eyes) or phaco-viscocanalostomy with Ologen implant (OloPhacovisco group) (40 eyes). Follow-up period was 2 years; Nd:YAG laser gonio-puncture was performed in cases where the IOP was elevated above 21 mmHg after discontinuation of corticosteroid eye drops at any follow-up visit. No significant operative or post-operative complications (other than failure) were encountered in either group. At 2 years follow-up, the mean IOP level was statistically significantly decreased in the OloPhacovisco group (p = 0.02) and complete success occurred in 23 eyes (59.0 %) in the Phacovisco group and in 32 eyes (80.0 %) in the OloPhacovisco group. There was a statistically significant higher success rate regarding complete success in patients that received Ologen implant (p = 0.04). The authors concluded that Ologen implant improved the success rate of phaco-viscocanalostomy. Moreover, these researchers stated that larger studies with longer follow-up periods are needed to confirm the safety and efficacy of this device in viscocanalostomy. The main drawbacks of this study were the relatively small sample size (40 eyes in the OloPhacovisco group) and short follow-up period (2 years).

Ab Interno Canaloplasty (ABiC)

In a retrospective, cohort outcome study, Davids and colleagues (2019) examined if the ab interno canaloplasty (ABiC) is a reasonable minimally invasive method to significantly reduce the IOP and number of anti-glaucomatous medications over a certain period of time in adults with POAG. A total of 36 eyes of 28 POAG patients (mean age of 74.8 ± 9.3 years) with an IOP above target pressure were included; ABiC was performed in all subjects as sole procedure in pseudophakic eyes (n = 20) or in combination with cataract surgery in phakic eyes (n = 16); IOP and the number of anti-glaucomatous medications were evaluated pre-operatively, day 1, week 6, month 3, month 6, and month 12. IOP decreased from 19.8 ± 4.1 to 13.8 ± 3 mmHg at 12 months follow-up (n = 21, p < 0.001). The IOP reduction showed significant results at all time-points (1 day p < 0.001; 6 weeks p < 0.001; 3 months p < 0.001; 6 months p = 0.001; and 12 months p < 0.001). Glaucoma therapy was stabilized at 2.1 ± 1.6 number of anti-glaucomatous medications after 12 months post-operatively. There was no significant difference in the number of anti-glaucomatous medication at 12 months follow-up (p = 1.0). No major peri-operative complications were reported. The authors concluded that the ABiC effectively lowered the IOP in POAG in the short-term follow-up of 12 months; however, a reduction of glaucoma therapy could not be attained and should be discussed with the patients before surgery.

Canaloplasty for the Treatment of Pseudo-Exfoliation Glaucoma

Hasanov and Kasimov (2018) examined the safety and efficacy of phaco-canaloplasty in patients with concomitant advanced pseudo-exfoliation glaucoma and cataract. The study included 56 patients (57 eyes) who underwent phaco-canaloplasty guided by Glaucolight microcatheter. All patients were followed up for 48 months. Visual acuity (VA), changes of intra-ocular pressure (IOP), use of glaucoma medications, incidence of complications, as well as post-surgical interventions were examined. Mean pre-operative IOP decreased significantly from 29.8 mmHg (15.8 to 61.6) with a mean of 1.92 (0 to 3) glaucoma drops to 12.9 mmHg (11.0 to 19.6) with a mean of 0.12 (0 to 3) drops, respectively 48 months after phaco-canaloplasty. Mean VA increased from pre-operative 0.15 (0.01 to 0.8) to 0.6 (0.01 to 1.2). The most frequent complications included intra-operative perforation of Descemet's membrane (4 eyes, 7 %) and hyphema (37 eyes, 65 %), IOP spikes (4 eyes, 7 %) and inflammation (4 eyes, 7 %) in the early post-operative period. The authors concluded that phaco-canaloplasty in eyes with concomitant advanced pseudo-exfoliation glaucoma and cataract re-established the natural outflow system and led to significant IOP reduction with minimal risk of intra- and post-operative complications.

Gabai et al (2019) carried out a meta-analysis on the safety and efficacy of trabeculectomy (TE) and non-penetrating glaucoma surgery (NPGS) techniques in patients with primary open-angle glaucoma (POAG), pseudo-exfoliation glaucoma, pigmentary glaucoma, and normal-tension glaucoma. All studies were identified by searching electronic sources (PubMed, Medline, Scopus, and Embase) until February 5, 2018. Primary outcome was mean IOP reduction at 6, 12, and 24 months. Complications, number of anti-glaucomatous medications, and visual outcomes were also evaluated. A total of 21 studies were included; 10 studies compared TE with deep sclerectomy (DS), 5 with viscocanalostomy (VC), 1 study with both DS and VC, and 5 with canaloplasty (CP). TE was superior to DS, VC, and CP in reducing IOP at 6 and 12 months, and to DS at 24 months. When comparing TE to VC and to CP at 24 months, there was no significant difference in IOP reduction. Hypotony, choroidals, anterior chamber shallowing or flattening, and cataract formation or progression were more associated with TE than with NPGSs. TE was more effective in reducing anti-glaucomatous medications than VC and CP. The authors concluded that TE was more effective in reducing IOP; and it presented a higher risk of complications as compared with NPGS, except for hyphema.

Kodomskoi et al (2019) noted that significant IOP reduction was achieved using a novel suture-probe canaloplasty (SPCP) procedure in patients with glaucoma. The effect and low rate of surgical complications were comparable with those of iTrack canaloplasty. Ab externo canaloplasty using the iTrack microcatheter has been established as a safe surgical procedure to treat OAG. These researchers described the results of a novel technique using a cost-efficient suture-probe as an alternative to iTrack canaloplasty and presented 12-month follow-up results. SPCP was carried out on 50 eyes of 50 patients with POAG, pseudo-exfoliation glaucoma, and steroid-induced glaucoma. The mean ± SD pre-operative IOP was 21.9 ± 7.0 mm Hg. A suture-probe was used to dilate Schlemm canal and to place a trabecular tensioning suture. Post-operative results were noted and statistically analyzed on the day of discharge from the clinic, and at 1.5, 3, 6, and 12 months of follow-up. In all eyes, the mean post-operative IOP 12 months after SPCP was 13.7 ± 3.0 mm Hg. The number of medications decreased from 2.8 ± 0.9 to 0.1 ± 0.4, and VA was 0.3 ± 0.3 logMAR. Post-operative course and complications included: hyphema of greater than 1 mm (2 %); micro-hyphema (4 %); bleb leakage (2 %); bleb suture (2 %); laser gonio-puncture (18 %); laser suture lysis (4% ); scleral flap lifting (4 %); and iris incarceration following laser gonio-puncture (4 %). The authors concluded that SPCP was an inexpensive procedure that could achieve significant IOP reduction in patients with glaucoma. The IOP-lowering effect and low rate of surgical complications were very similar to those of iTrack canaloplasty.

Seuthe et al (2021) examined the long-term safety and efficacy of the modified canaloplasty technique with additional supra-choroidal drainage in patients with pseudo-exfoliation glaucoma. This retrospective clinical trial included 131 patients with pseudo-exfoliation glaucoma who underwent canaloplasty with supra-choroidal drainage (scD). A total of 111 of 131 patients underwent the follow-up examination after 48 months. Primary endpoints were the pressure-lowering and drug-sparing effect as well as the success rates. Secondary endpoints were intra- and post-operative complications and the occurrence of secondary surgical interventions. The IOP was reduced by 45.8 % after 12 months (from baseline 23.4 ± 5.1 mmHg to 12.7 ± 2.2 mmHg) and by 45.1 % after 4 years (12.8 ± 2.2 mmHg) (p < .001). The mean number of IOP-lowering medication decreased significantly from 3.4 at baseline to 0.6 after 12 months and to 1.0 after 4 years. The IOP-reducing effect was even stronger in those cases in whom canaloplasty+ scD was combined with cataract surgery (49.4 % after 12 months and 47.6 % after 4 years). No serious complications were observed. The authors concluded that the modified surgery technique of canaloplasty with supra-choroidal drainage was a safe and effective way of reducing IOP in patients with pseudo-exfoliation glaucoma.

Furthermore, an UpToDate review on “Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis” (Jacobs, 2021) states that “Other possible risk factors for developing open-angle glaucoma include myopia, pseudo-exfoliation, low diastolic perfusion pressure, cardiovascular disease, a history of prior vitreoretinal surgery, and hypothyroidism”.

Canaloplasty and Trabeculotomy Ab Interno with the OMNI System Combined with Cataract Surgery for the Treatment of POAG

Brown et al (2020) stated that micro-catheterization and visco-dilation of Schlemm canal or canaloplasty has been shown to reduce intra-ocular pressure (IOP) in open-angle glaucoma (OAG). In separate studies, trabeculotomy carried out with a catheter or a suture has been shown to lower IOP. The OMNI Surgical System was the 1st micro-invasive glaucoma surgery device that enables surgeons to carry out canaloplasty and trabeculotomy in succession with a single instrument. These investigators reported the early results with this multi-modal surgical technology. Eyes with OAG underwent phacoemulsification combined with 180 degrees of canaloplasty, followed by 180 degrees of trabeculotomy using the OMNI device. The pre-operative IOP was determined by the mean value of IOPs from the 2 visits before surgery measured using a Goldmann applanation tonometer. The post-operative IOP was determined by the mean value of IOPs from the last 3 post-operative visits. The pre-operative IOP was used to stratify the eyes into 3 groups. In each group, a paired 1-sample t-test was used to examine if there were statistically significant changes in IOP compared with baseline as a result of the operation. The study evaluated 41 eyes (24 patients). The mean IOP reduction in all eyes was 5.6 ± 4.5 mm Hg (p < .001). The mean follow-up was 4.1 ± 1.9 months. There was a significant correlation between the magnitude of IOP reduction and pre-operative IOP that was best described by a linear relationship (R2 = 0.7, p < .001). In eyes with a pre-operative IOP higher than 22 mm Hg, the mean IOP reduction was 9.6 ± 3.5 mm Hg (p < .001). In eyes with a pre-operative IOP higher than 16 mm Hg, 100 % had a decrease in IOP post-operatively. There were no complications related to cataract surgery. There were 2 cases of hyphema (4 %) that cleared within 1 week. There was no protocol for reducing medication usage post-operatively. The mean number of medications decreased slightly; however, this was not significant. No eye has required secondary glaucoma surgery. The authors concluded that this study found that OMNI combined with phacoemulsification reduced IOP. The magnitude of pressure lowering with OMNI was highly correlated with the pre-operative IOP. This was a similar finding to a previous study of the original iStent. However, the phaco-OMNI surgery had a mean overall IOP reduction of 5.6 mm Hg, whereas the mean phaco-iStent IOP reduction was 3.2 mm Hg.

These investigators stated that the decision to carry out 180 degrees of OMNI in combined surgery was based on the objective of maximizing efficacy while minimizing the extent of surgery and to conduct a smaller rather than a larger procedure. Some surgeons may choose to perform 360 degrees of canaloplasty with 180 degrees of trabeculotomy or some other combination. The extent of trabeculotomy and canaloplasty could be titrated easily depending on the clinical context. Patients in this study generally had mild-to-moderate glaucoma; however, some had more advanced disease. Follow-up was limited (mean of 4.1 months) because the OMNI device has only been available in the U.S. since mid-2018. There was no protocol for reducing medications; however, the level of pressure reduction suggested that some patients may benefit from a reduction in medications. However, longer-term studies are needed to examine the durability of reduction in IOP and the opportunity for decreasing the medication burden. Moreover, these researchers stated that the OMNI device may give surgeons a safe, implant-free micro-invasive glaucoma surgery option for combining trabeculotomy and canaloplasty in a single procedure. Combined with phacoemulsification the device reduced IOP more in eyes with higher pre-operative pressures; thus, eyes with the greatest need for IOP reduction may experience the greatest benefit.

In a retrospective, single-center, consecutive, case-series study, Hughes and Traynor (2020) reported treatment outcomes of ab interno canaloplasty using the Visco360 and Omni system devices as a standalone procedure or combined with cataract surgery in patients with open-angle glaucoma (OAG). A total of 89 eyes of 64 patients aged 43 to 91 with OAG treated with ab interno canaloplasty between January 2018 and September 2019 were included in this trial. Eyes with previous incisional glaucoma surgery and eyes with less than 90 degrees of viscodilation were excluded. Patients underwent ab interno canaloplasty as a stand-alone procedure or in conjunction with cataract surgery. Ab interno canaloplasty was carried out with either the Visco360 or Omni System devices. Treatment consisted of viscodilation without trabeculotomy. Primary outcome measures were mean IOP and mean number of glaucoma medications. Additional analysis included the impact of degrees of treatment on health outcomes. Pre-operative mean IOP was 24.5 ± 8.3; the number of pre-operative glaucoma medications was 2.5 ± 1.3. At 18 months post-operative, the mean IOP was reduced 36 % to 15.8 ± 2.5 (p < 0.001) and glaucoma medications were reduced 32 % to 1.7 ± 1.5 (p < 0.05). Higher pre-operative IOP was significantly correlated with increased IOP lowering. Reduction of mean IOP and medications were not significantly different between standalone ab interno canaloplasty versus cataract surgery/ab interno canaloplasty. Reduction of mean IOP and medications were not significantly different between patients with 180 degrees of treatment vs 360 degrees of treatment. The authors concluded that ab interno canaloplasty reduced IOP and glaucoma medication use in patients with OAG whether as a standalone surgery or in combination with cataract surgery.

The authors stated that study limitations included the relatively small number of standalone surgery eyes. Nevertheless, the standard deviation at 18 months for this group was similar to that for the overall group providing some confidence in the point estimate for the mean. With 72 eyes in the combined with cataract group, the results were reasonably robust. This study was also limited by the weaknesses inherent to retrospective studies including selection bias and variable follow-up. To mitigate against this potential bias, all eligible patients were included with minimal exclusion criteria. Both eyes from a given patient were included in the analysis when each eye met the eligibility criteria; thus, complete independence of all variates was not satisfied. The consequence of this was potential under-estimation of variability in the findings; however, the measured standard deviation for the IOP at baseline was greater than generally observed in published studies (e.g., 3 to 4 mmHg) arguing against such bias. Nevertheless, this potential bias should be considered when interpreting the results. In the authors’ view, the increased number of surgical cases and the consequent greater likelihood of revealing infrequent safety issues more than balanced this weakness. The study did not attempt to explain how ab interno canaloplasty reduced IOP; and there was no further investigation to understand why some eyes were not able to receive a full circum-navigation of 360 degrees.

In a retrospective, single-arm, multi-center study, Hirsch and colleagues (2021) provided safety and effectiveness outcomes 12 months post-surgically for sequential canaloplasty and trabeculotomy with the OMNI System combined with cataract surgery in mild-to-moderate OAG. The trial was carried out in 11 ophthalmology practices and surgery centers located in 8 states (AL, AR, CA, KS, LA, MO, NY, TX). A total of 12 surgeons contributed 81 patients meeting eligibility criteria: OAG, 12-month follow-up, medicated IOP of less than or equal to 36 mmHg on less than or equal to 4 medications pre-operatively. Analysis stratified by baseline (BL) IOP; greater than 18 mmHg (group 1), less than or equal to 18 mmHg (Group 2). Success defined as proportion with greater than or equal to 20 % reduction in IOP, or IOP between 6 and 18 mmHg (inclusive) AND on the same or fewer medications without secondary surgical intervention (SSI). Other endpoints included mean IOP and medications at 12 months; and safety outcomes included BCVA and AEs. Primary success was met by 79 % (Group 1) and 81 % (Group 2). Mean IOP was reduced in Group 1 (21.9 to 15.1 mmHg, p < 0.0001), and remained controlled in Group 2 (14.1 to 13.4 mmHg, p = 0.3177). Medications went from 2.0 ± 1.3 to 1.1 ± 1.1 (Group 1) and from 1.6 ± 1.3 to 0.9 ± 1.2 (Group 2); AEs were typical for cataract or angle surgery: mild inflammation (11 %), IOP spikes (5 %), hyphema (4 %); and 4 patients (5 %) required an SSI. The authors concluded that OMNI system provided effective IOP reduction, sustained IOP control, and meaningful medication reduction for up to 12 months post-operative. The OMNI System provided the ability to perform a circumferential viscodilation and ab interno trabeculotomy. This newly introduced device showed promising preliminary results for the management of moderate and advanced glaucoma; however, limited data are currently available regarding its safety and efficacy because of the short time this device has been marketed.

In a prospective, institution review board (IRB)-approved, multi-center study, Pyfer et al (2021) analyzed diurnal IOP data (9 AM, 12 PM, and 4 PM) from a prospective 12-month trial of the OMNI Surgical System in OAG)patients with the aim of examining the effect of MIGS surgery on the amplitude of the diurnal IOP profile pre- and post-operatively. A total of 15 ophthalmology practices and surgery centers located in 14 states in the U.S. Subjects included patients treated with canaloplasty (360°) and trabeculotomy (180°). Patients had cataract and mild-to-moderate OAG with IOP of less than or equal to 33 mmHg on 0 to 4 hypotensive medications. Post-hoc analysis of diurnal IOP data from the multi-center GEMINI study. Analysis included comparison of IOP pre-operatively and at month 12 for each of the diurnal time-points, 9 AM, 12 PM, and 4 PM, change in magnitude of spread between the maximum IOP and minimum IOP for each patient and the proportions of patients pre-operatively and at month 12 with IOPs at or below 25, 21, 18, and 15 mmHg, average variability (standard deviation [SD] of the 9 AM, 12 PM, and 4 PM IOP) pre-operatively and at month 12. A total of 128 patients included in this analysis. IOP at each diurnal timepoint was significantly lower post-operatively (p < 0.0001). The difference between highest and lowest IOP measurement for each patient averaged 2.8 mmHg pre-operatively (SD 2.4, MAX 14, MIN 0) and 1.8 mmHg (SD 1.7, MAX 10, MIN 0) month 12 (p < 0.00001). The proportion with IOP less than or equal to 25, 21, 18, and 15 mmHg increased 75 % to 97 %, 27 % to 88 %, 1 % to 79 %, and less than 1 % to 56 %, respectively. The average variability was greater at all time-points pre-operatively (p < 0.0001). The authors concluded that the findings of this study demonstrated that eyes with OAG could benefit from an overall decreased IOP and degree of IOP fluctuations for as long as 12 months after surgical treatment with canaloplasty and trabeculotomy. Moreover, these researchers stated that further study with a greater sample size and longer follow-up are needed and ongoing. Study using other minimally (or micro) invasive glaucoma surgery (MIGS) procedures to determine the generalizability of these results are also needed.

The authors stated that this study had several drawbacks. First, analysis of fluctuation was not an a priori objective of the GEMINI study; however, these researchers had employed appropriate statistical analyses including testing for normality and using distribution-free methods where appropriate, controlling for multiplicity using Bonferroni correction, and limiting the data interrogation to focus on intra-patient IOP variability. Second, this study did not address progression; the GEMINI study was not designed to assess progression. Automated perimetry was performed at pre-operative baseline and at month 12 primarily for eligibility and safety reasons; however, there were no AEs for worsening of visual field mean deviation. Third, there was not an untreated control group. Including a “no treatment” or placebo control is problematic for ethical reasons in a 12-month long study such as GEMINI where patients have a progressive and potentially blinding disease. However, the analysis did compare pre-operative with post-operative IOP data for the same patients; effectively each patient serving as their own control. Finally, these findings suggested that MIGS could be effective in controlling IOP fluctuations; however, the data were restricted to eyes treated with canaloplasty and trabeculotomy using the OMNI Surgical System. These investigators did not know if these findings could be generalized to other MIGS procedures and implants.

In a prospective, multi-center, IRB-approved study, Gallardo et al (2021) reported interim 6-month safety and effectiveness outcomes of 360° canaloplasty and 180° trabeculotomy using the OMNI Surgical System concomitantly with phacoemulsification in patients with OAG. This trial included a total of 15 multi-subspecialty ophthalmology practices and surgery centers located in 14 states (Alabama, Arizona, Arkansas, Florida, Georgia, Iowa, Kansas, Montana, Nebraska, North Dakota, Oklahoma, Pennsylvania, Texas, and Wisconsin). Subjects included patients treated with canaloplasty (360°) and trabeculotomy (180°). Eligible patients had cataract and mild-to-moderate OAG with IOP of less than or equal to 33 mmHg on 1 to 4 hypotensive medications. Medication wash-out before baseline diurnal IOP (Goldmann). Effectiveness outcomes included mean IOP and medications. Safety outcomes included AEs, BCVA and SSI. Analysis included descriptive statistics and t-tests evaluating change from baseline. A total of 137 patients were enrolled and treated. Mean diurnal IOP after washout was 23.8 ± 3.1 mmHg at baseline. At month 6, 78 % (104/134) were medication free with IOP of 14.2 mmHg, a mean reduction of 9.0 mmHg (38 %); 100 % (104/104) had a greater than or equal to 20 % reduction in IOP and 86 % (89/104) had IOP greater than or equal to 6 and less than or equal to 18 mmHg. The mean number of medications at screening was 1.8 ± 0.9 and 0.6 ± 1.0 at month 6. AE included transient hyphema (4.6 %) and IOP elevation greater than or equal to 10 mmHg (2 %). There were no AE for loss of BCVA or recurring hyphema. There were no SSI. The authors concluded that canaloplasty followed with trabeculotomy and performed concomitantly with phacoemulsification had favorable intra- and peri-operative safety, significantly reduced IOP and anti-glaucoma medications through 6 months in eyes with mild-to-moderate OAG. Moreover, these researchers stated that full 12-month results of the entire cohort will be reported upon study completion.

In a retrospective, uncontrolled, single-surgeon study, Klabe and Kaymak (2021) reported on the IOP, medication outcomes at 24 months following trabeculotomy/viscodilation using the OMNI Surgical System as a standalone procedure in medically uncontrolled mild-to-moderate OAG. IOP and medication data were collected before surgery and through 24 months. Safety data included adverse events (AEs) and the need for additional surgery. Pre-operative medication washout, Goldmann tonometry as well as number of medications and AEs at each time-point were examined. Primary outcomes included changes in IOP and medications; 2-sided paired t-tests compared values at each follow-up with baseline, significance p = 0.05. Secondary outcomes included proportion of eyes with IOP reduction of greater than or equal to 20 %, on fewer medications, and medication-free at each time-point. This analysis included data from 38 eyes of 27 subjects. Mean (standard deviation [SD]) baseline IOP was 24.6 (3.0) mmHg and through 24 months ranged from 12.6 to 14.9 mmHg (p < 0.0001), representing reductions of 10.0 to 12.0 mmHg. Mean medications were 1.9 (baseline) and through 24 months ranged from 0.0 to 0.5 (70.6 % to 100 % reduction) (p < 0.0001). At month 24, mean IOP was 14.9 mmHg (−10.0 mmHg), and 100 % of eyes achieved IOP reduction greater than 20 % from baseline; mean medication use was 0.5 (−1.4 medications, p < 0.0001), 84.6 % of eyes using greater than 1 fewer medication, and 57.7 % were medication-free. The most common AE was intra-operative hyphema (44.7 %); all resolved spontaneously. There were 2 secondary procedures for IOP control. The authors concluded that the OMNI Surgical System provided clinically relevant and statistically significant reductions in both IOP and medications with an excellent safety profile and should be considered in phakic or pseudophakic eyes with mild-to-moderate OAG requiring IOP or medication reduction, or both.

The authors stated that this study had several drawbacks. It was a retrospective, uncontrolled, single-surgeon study. Moreover, the eye was the unit of analysis and not the patient. As this was a non-comparative, non-hypothesis testing, descriptive study, the main effect (if any) of the lack of independence among variates would be a potential under-estimate of variability. These researchers felt that the inclusion of all available eyes strengthened the safety and effectiveness outcomes reported. It should also be noted that this study included both phakic and pseudophakic eyes, as well as both secondary OAG (pseudo-exfoliative glaucoma [PXF]) and primary OAG (POAG). While sample sizes were too small (n = 27 patients) to permit formal analysis, final mean IOP was similar in phakic and pseudophakic eyes, with no lens-related AEs (aside from transient lens-cornea touch in 1 phakic eye) reported. Likewise, final mean IOP was similar in PXF and POAG suggesting that canaloplasty with trabeculotomy is an effective treatment for IOP reduction in these often more challenging cases. Furthermore, while many minimally invasive glaucoma surgeries (MIGS) studies limited outcomes to IOP and medication parameters, this study also reported functional glaucoma status in all patients followed for 24 months, with no change in the mean visual field mean deviation [VFMD] over the 2-year follow-up period.

Furthermore, an UpToDate review on “Open-angle glaucoma: Treatment” (Jacobs, 2021) states that “All patients with glaucoma should receive treatment upon diagnosis. Pharmacologic therapy, laser therapy (trabeculoplasty), and/or surgery (trabeculectomy) have been shown to lower intraocular pressure (IOP) in randomized trials. However, there are little data on their efficacy in preventing deterioration of vision. A limitation of available evidence is the dual challenge of accounting for ongoing advances in all three therapeutic strategies and assessing a key outcome, visual deterioration, that may take many years to develop”. Moreover, this review does not mention canaloplasty and phacoemulsification as management / therapeutic options.

In a prospective, IRB-approved multi-center study, Gallardo et al (2022) reported the 12-month effectiveness outcomes of 360° canaloplasty and 180° trabeculotomy using the OMNI surgical system in combination with phacoemulsification in patients with mild-moderate open-angle glaucoma (OAG) and visually significant cataract. This trial was carried out in 15 multi-subspecialty ophthalmology practices and surgery centers located in 14 U.S. states. Subjects were patients treated with canaloplasty (360°) and trabeculotomy (180°); eligible patients had cataract and mild-moderate OAG with IOP of less than or equal to 33 mmHg on 1 to 4 hypotensive medications. Unmedicated post-washout mean diurnal IOP (DIOP) was greater than or equal to 21 and less than or equal to 36 mmHg. Medication washout was performed pre-operatively and before month-12 DIOP. Effectiveness outcomes were IOP and IOP lowering medication use. Safety outcomes included AEs and SSIs. Evaluations were carried out at 1, 3, 6, and 12 months. A total of 149 subjects underwent surgery and 120 were included in the final effectiveness analysis. Mean (SD) unmedicated diurnal IOP was reduced from 23.8 (3.1) mmHg at baseline to 15.6 (4.0) at month 12 (-35 %) and medications (before washout) were reduced from 1.8 (0.9) at baseline to 0.4 (0.9) at month 12 (-80 %). At month 12, 84.2 % of eyes achieved IOP reductions of greater than 20 % from baseline, 80 % of eyes were medication-free, and 76 % of eyes achieved IOP between 6 to 18 mmHg inclusive; AEs were uncommon. Most were mild and self-limited including transient hyphema (9 of 149; 6 %) and transient IOP elevations (3 of 149; 2.0 %). No eyes needed SSIs or experienced loss of VA that was attributable to the device or procedure. The authors concluded that canaloplasty and trabeculotomy carried out with the OMNI surgical system at the time of phacoemulsification significantly lowered unmedicated mean DIOP and medication use 12 months post-operatively, with an excellent safety profile. This procedure should be considered for eyes with mild-moderate OAG to reduce IOP, medication burden, or both

The authors stated that the lack of a control group was a drawback that precluded quantifying the contribution of elements from the phacoemulsification and OMNI procedures (as would be possible with a phacoemulsification-only arm) or comparison of OMNI to other MIGS procedures (as would be possible with an active comparator arm). Phacoemulsification alone is known to lower IOP and the need for IOP-lowering medications in glaucomatous eyes. These researchers have tried to mitigate this limitation by designing the statistical analysis plan around the relevant outcomes of phacoemulsification-only groups (which have been remarkably consistent albeit greater than what has been typically reported in other publications) in recent pivotal MIGS trials, specifically powering the study to detect an effect size in excess of that expected by phacoemulsification alone in eyes with mild-moderate OAG. The decision to design this study without a cataract surgery only control group was not made lightly. First, the availability of published data for large cohorts of similarly defined patient populations undergoing phacoemulsification only allowed reasonable estimation of the cataract surgery only treatment effect. Second, in the early 2010ʹs when the pivotal studies for iStent, Hydrus, and CyPass were initiated, the treatment landscape for mild-to-moderate glaucoma in the U.S. was very different. MIGS was a new modality with limited availability and options. Standard treatment was generally medical (drops) or laser (SLT). In contrast, by 2019 when the present study was designed there were several MIGS options available to patients and surgeons with increasing adoption. In this evolving environment, execution of a trial where many patients would be randomized to a “no treatment” (aside from cataract surgery) control would have faced increased unwillingness of patients to participate and would arguably be less ethically sound given the many new therapeutic options available for mild-to-moderate glaucoma.

In a retrospective, observational study, Toneatto et al (2022) examined the effectiveness of ab-interno micro-catheterization and 360° viscodilation of Schlemm's canal (SC) performed with OMNI visco-surgical system in OAG together or not with phacoemulsification. A total of 80 eyes from 73 patients with mild-to-moderate OAG underwent ab- interno SC viscodilation carried out with the OMNI system; 50 eyes (Group 1) underwent only SC viscodilation, while 30 eyes (Group 2) underwent glaucoma surgery + cataract extraction. Primary success endpoint at 12 months was an IOP reduction higher than 25 % from baseline with an absolute value of 18 mmHg or lower, either on the same number or fewer ocular hypotensive medications, without further interventions. Secondary effectiveness endpoints included mean IOP, number of medications and comparison of outcomes between groups. Safety endpoints consisted of BCVA, AEs, and subsequent surgical procedures. Primary success was achieved in 40.0 % and 67.9 % in Groups 1 and 2, respectively. Mean IOP at 12-month follow-up showed a significant reduction in both groups (from 23.0 to 15.6 mmHg, p < 0.001, and from 21.5 to 14.1, p < 0.001, in Groups 1 and 2, respectively). Mean medication number decreased in both groups (from 3.0 to 2.0, p < 0.001 and from 3.4 to 1.9, p < 0.001, in Groups 1 and 2, respectively); AEs included hyphema (2 eyes), mild hypotony (4 eyes), IOP spikes 1 month after surgery (1 eye); 12 eyes (15.0 %) required subsequent surgical procedures. No BCVA reduction was observed. The authors concluded that viscodilation of SC using the OMNI viscosurgical system, with or without cataract extraction, appeared to be a promising surgical procedure to effectively control and reduce IOP with a highly safer profile, even if a high percentage of eyes needed a medical treatment. Moreover, these researchers stated that further studies are needed to report long-term results and complications, and to examine the real advantage of an associated trabeculotomy.

The authors stated that the drawbacks of this trial included the retrospective nature of collected data, the relatively low number of subjects included, the short follow-up period (12 months), and the enrollment of both eyes of the same patient in some cases. Furthermore, not all eyes were naive to prior surgery: 13 had already underwent previous major glaucoma surgery (trabeculectomy and deep sclerectomy). This choice was based on previous studies that have shown that canaloplasty can also be successfully carried out in patients with failed trabeculectomy in which the SC has been left mostly undamaged from previous filtering surgeries. There was no standardized protocol for reducing or increasing medications; however, the medical therapy was adjusted to reach the target IOP on a case-by-case basis. Follow-up was limited to 1 year. Due to the limited number of patients included in this cohort, it was difficult to examine the role and influence of glaucoma types on surgery between the groups. These investigators stated that future prospective studies are currently underway to aid in addressing this issue. In particular, longer-term studies on a larger group of prospectively enrolled patients are needed to evaluate the duration of IOP reduction with this surgical technique.

In a prospective, case-series study, Grabska-Liberek et al (2022) examined clinical outcomes of combined visco-dilation of Schlemm's canal and collector channels and 360° trabeculotomy as a standalone procedure or combined with cataract surgery in eyes with mild-to-moderate open-angle glaucoma (OAG). The OMNI glaucoma surgical platform was employed to carry out the procedure either combined with phacoemulsification or as a standalone procedure. Changes from baseline in IOP and IOP-lowering medications were evaluated through the first 12 months of a planned 24-month follow-up period. Among 17 eyes of 15 subjects, mean IOP was reduced from 20.4 mmHg to 12.7-13.7 mmHg through 12 months of follow-up (p < 0.001 at every time-point) and mean medications reduced from 2.5 to 0.1-0.6 (p < 0.001 at every time-point). IOP reductions in eyes undergoing stand-alone surgery were approximately 2 to 4 mmHg greater at each time-point compared to eyes undergoing surgery combined with phacoemulsification; this may be related to a higher baseline IOP in the former eyes (22.1 versus 18.5 mmHg); 6 eyes developed hyphema, of which 3 required wash-out for elevated IOP on the 1st post-operative day; 6 additional eyes had IOP elevations that resolved with medical management. The authors concluded that viscodilation of Schlemm's canal and collector channels paired with ab interno trabeculotomy performed with a single integrated instrument (OMNI), whether as standalone or combined with phacoemulsification, effectively lowered both IOP and the need for IOP-lowering medications through 12 months of follow-up. Moreover, these researchers stated that further study is needed to more robustly characterize outcomes and clarify the optimal use of this procedure. This study is ongoing and 24-month data will be reported when available.

The authors stated that drawbacks of this study included its relatively small sample size (n = 15) as well as the absence of a comparator group. This was a common drawback for studies of many of the minimally invasive glaucoma surgeries (MIGS) procedures, especially those cleared for marketing through the 510(k) equivalence-to-predicate pathway without the requirement for a pivotal trial, in which funding for well-designed and adequately-powered clinical trials is often not available.

In a retrospective, open-label, case-series study, Murphy et al (2022) reported that 12-month safety and effectiveness results for canaloplasty combined with trabeculotomy using the OMNI Surgical System in pseudophakic eyes or combined with cataract surgery in mild-to-moderate OAG. This trial was carried out in 16 centers in 11 U.S. states (AL, AR, CA, CT, KS, LA, MO, NY, SD, TN, TX). A total of 136 eligible patients from 20 surgeons: mild-to-moderate OAG (VFMD) not worse than − 12 dB), 12-month follow-up, pre-operative medicated IOP of greater than 18 mmHg and 36 mmHg or less on 5 medications or less. One eye per patient enrolled. Endpoints included proportion with 20 % or greater reduction in IOP or IOP between 6 and 18 mmHg (inclusive) and on the same or fewer medications without secondary surgical intervention (SSI) (primary success), mean IOP, change in IOP, ocular hypotensive medication use, and proportion of patients with a 20 % or greater reduction in IOP at 12 months. Safety: AE and best corrected visual acuity (BCVA). Primary success was met by 71 %. Mean IOP was reduced (22.3 to 15.9 mmHg, p < 0.0001). Medications went from 1.9 ± 1.3 to 1.3 ± 1.2 (p < 0.001). AE were mild and as expected for angle surgery. The most frequent AE were BCVA loss (6 %), mild inflammation (4 %), IOP elevation (3 %), and clinically significant hyphema (3 %). There were 4 (3 %) SSI. The authors concluded that the OMNI Surgical System provided effective IOP reduction, sustained IOP control, and meaningful medication reduction for up to 12 months post-operative; this trial confirmed and extended the results from the ROMEO Trial.

The authors stated that this trial had several drawbacks. First, eligibility required a pre-operative IOP of greater than 18 mmHg that was measured at 1 visit (mean of 2 repeated measurements). While this could create the risk of regression to the mean it was, in the authors’ view, an acceptable risk that would likely be relevant for only a small fraction of the study population. The alternative of using 2 or more pre-operative visits to obtain a mean pre-operative IOP would likely have been confounded with differences in number and class of medications used, given the generally poor IOP control pre-operatively. Moreover, to be comparable to ROMEO 1, it was important to match eligibility criteria. Second, while there was overlap in investigational sites/surgeons between ROMEO 2 and ROMEO 1, which could arguably account for the consistency of results, ROMEO 2 included 5 new centers with 7 new surgeons who had not participated in the original ROMEO Trial. The new centers and surgeons would certainly have introduced some diversity and variability beyond what was measured. Nevertheless, the overall similarity in outcomes suggested generalizability and robustness. Third, this trial, was limited to 12 months of post-operative follow-up and additional follow-up beyond 12 months would allow better characterization of the durability of the treatment effect. These researchers believed such data would be forthcoming with time. Similar to the original ROMEO study, ROMEO 2 was retrospective. Protocol defined measurement methods (e.g., for IOP), strict surgical procedural guidelines, rules for medication introduction or discontinuation, and washout of IOP-lowering medication before treatment and at the endpoint were commonplace in prospective clinical trials but were not in retrospective studies. While this lack of standardization could be viewed as a weakness, it was in fact a core strength of this study. No 2 ophthalmologists treated glaucoma in exactly the same way. Individual practitioners have different thresholds for surgical intervention, differing ideas regarding IOP targets and treatment escalation, and different ideas regarding when a medication can be discontinued. A prospective “one size fits all” clinical trial could not capture this diversity of practice; thus, generalizability may be limited. However, in a study such as ROMEO or ROMEO 2, this diversity was embraced and the results may in some ways better inform other surgeons of the outcomes they might achieve in their own patients.

In a retrospective, single-center study, Ondrejka et al (2022) examined the long-term safety and effectiveness of canaloplasty in reducing IOP and use of IOP-lowering medications in eyes with OAG. A total of 206 eyes from 130 patients were included. Canaloplasty was carried out using the VISCO360 or OMNI Surgical System as a stand-alone procedure in 22 eyes and concomitantly with cataract extraction (CE) in 185 eyes with chronic OAG insufficiently controlled or intolerant to IOP-lowering medications. The number of hypotensive medications and IOP were recorded at baseline, day 1, week 1, month 1, month 3, and every 3 months thereafter, with the last follow-up visit at 36 ± 6 months post-operatively. Patients were stratified by baseline IOP (Group 1, IOP greater than18 mm Hg; Group 2, IOP 18 mm Hg or lower). Treatment success in Group 1 was defined as a reduction in IOP and the use of IOP-lowering medications; Group 2 success was defined as maintenance of a lower IOP and a reduction in medication use. The pre-operative mean IOP of both groups was 21.1 ± 8.8 mm Hg, with a mean of 2.0 ± 0.9 hypotensive medications. The primary success endpoint was met by 73 % of patients, with a mean IOP reduction in Group 1 (131 eyes; 21.8 to 15.6 mm Hg, p < 0.0001) and a maintenance of IOP control in Group 2 (76 eyes; 15.4 to 13.9 mm Hg, p = 0.24). Medications decreased from 2.2 ± 0.9 to 0.9 ± 1.1 in Group 1 (p = 0.024) and from 1.8 ± 0.8 to 0.7 ± 1.0 in Group 2 (p = 0.003). The authors concluded that canaloplasty carried out using the VISCO360 or OMNI Surgical System was a safe, tissue-preserving, and effective MIGS option that allowed surgeons to perform multiple procedures (canaloplasty and CE) using a clear corneal incision or perform a stand-alone procedure in phakic or pseudophakic eyes. Both devices successfully and consistently performed canaloplasty and achieved statistically significant and clinically meaningful reductions in IOP and the use of medications in adult patients with OAG. Ongoing data collection is expected to better describe the persistence of these real-world outcomes, and further studies are needed to confirm the persistence of benefit of this intervention in patients with OAG.

The authors noted that their findings were based on a retrospective, single-center, case-series study. As both eyes from 1 patient may have been included in the analysis when both met the eligibility criteria, the statistical analysis may be limited in the ability to consistently maintain independent data points. The majority of eyes (89.8 %) included in this analysis received canaloplasty in conjunction with cataract surgery. As cataract is the most common co-morbidity in patients with glaucoma, simultaneous cataract and glaucoma surgery are routine in practice. In such cases, IOP reduction can be attributed to both the procedures. It was noteworthy that, in small subgroup (n = 22) included in this study eyes that underwent a stand-alone canaloplasty, the percentage reduction in IOP was 40 % (from 25.9 to 15.5 mm Hg with a maintained medication burden), which was greater than that observed in the overall cases included in the analysis, the majority of which received OMNI in conjunction with cataract surgery (28 % reduction in IOP with a 62 % reduction in medication burden). The readers should also take into consideration the number of medications used in each group at 36 months. Cataract surgery in patients with glaucoma has been previously observed to achieve an IOP reduction ranging between 0.6 mm Hg and 2.5 mm Hg at 1 year. Moreover, these researchers noted that patient inclusion criteria were purposefully broad to reflect real-world practice. This trial also lacked a control group to compare outcomes more reliably over time with other interventions. Nevertheless, the durable efficacy and favorable safety profile demonstrated after 36 months of follow-up suggested that ab interno canal viscodilation with the VISCO360 or OMNI Surgical System is an attractive and minimally invasive strategy for the treatment of patients with OAG.

The National Institute for Health and Clinical Excellence’s interventional procedures guidance on “Ab interno canaloplasty for open-angle glaucoma” (NICE, 2022) stated that the evidence on the safety of ab interno canaloplasty for OAG shows no major safety concerns. The NICE guidance also noted that the evidence on the effectiveness ab interno canaloplasty for OAG is limited in quality and quantity, especially in the long-term; thus, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

In a retrospective, multi-center study (7 multi-subspecialty ophthalmology practices located in AK, CA, KS, LA, MO and NY), Williamson et al (2023) provided extended safety and effectiveness follow-up for eyes treated with circumferential canaloplasty and trabeculotomy (CP+TR) that were included in the 12-month ROMEO study. Eligible eyes had mild-moderate glaucoma and were treated with CP+TR with cataract surgery or as a standalone intervention were included in this analysis. Main outcome measures were mean IOP, mean number of ocular hypotensive medications, mean change in number of medications, proportion of patients with a 20 % or greater reduction in IOP or with IOP of 18 mmHg or less, and proportion of medication-free patients. Safety outcomes were AEs and SSI. A total of 8 surgeons at 7 centers contributed 72 patients stratified by pre-operative IOP: greater than 18 mmHg (Grp1), 18 mmHg or less (Grp2). Mean follow-up of 2.1 years (minimum of 1.4 years, maximum of 3.5 years). 2-year IOP (SD) was 15.6 mmHg (− 6.1 mmHg, − 28 % from baseline) on 1.4 medications (− 0.9, − 39 %) for Grp1 with cataract surgery; 14.7 mmHg (− 7.4 mmHg, − 33 % from baseline) on 1.6 medications (− 0.7, − 15 %) for Grp1 stand-alone, 13.7 mmHg (− 0.6 mmHg, − 4.2 %) on 1.2 medications (− 0.8, − 35 %) for Grp2 with cataract surgery, 13.3 mmHg (− 2.3 mmHg, − 14.7 %) on 1.2 medications (− 1.0, − 46 %) for Grp2 stand-alone. The proportion of patients at 2 years with either a 20 % or greater IOP reduction or IOP between 6 and 18 mmHg and no increase in medication or SSI was 75 % (54 of 72, 95 % CI: 69.9 % to 80.1 %). One-third of patients (24 of 72) were medication-free whereas 9 of 72 were pre-surgical. No device-related AEs during extended follow-up; 6 eyes (8.3 %) required additional surgical or laser intervention for IOP control after 12 months. The authors concluded that CP+TR provided effective IOP control that was sustained for 2 years or more.

The authors stated that this study had several drawbacks. First, it was a retrospective chart review; thus, dependent on data collected in routine medical practice and not for the purpose of research. This meant that there is inherently more variability in the way in which procedures were carried out and data collected than would be the case in a prospective study. It also meant that there was inevitably more missing data, including factors that could influence outcomes that were not recorded. Nevertheless, the study included a relatively large number of patients from multiple research sites and multiple surgeons. These researchers believed that such outcomes did provide a realistic view of the effectiveness of the canaloplasty and trabeculotomy (OSS) in actual clinical practice and, importantly, durability of the treatment effect beyond 12 months. Such information will be of great value to surgeons considering the OSS for use in their practices. Second, the extended follow-up reported included only 7 of the original 11 ROMEO study sites. While the participating sites accounted for 86 % of the enrollment, the potential for unintended bias must be acknowledged. As the non-participating sites were, in general, low enrollers in ROMEO, there was arguably the possibility that higher enrollment sites were more experienced with the OSS, which might have resulted in a bias toward better outcomes reported here. These investigators believed this unlikely based on 2 observations: comparison of outcomes for the first 12 months from the overall ROMEO study population with those for the consistent cohort included in this study found no differences; 12-month mean IOP for the 18 patients at the non-participating sites was essentially identical to the mean for the 111 patients from participating sites (14.4 versus 14.3 mmHg). Third, there was a 35 % lost to follow-up rate at 24 months. While significant loss to follow-up is commonplace in retrospective studies, and it was not possible to ascertain the reasons for loss to follow-up, drop-outs due to AEs and non-response could not be ruled out. However, attrition was not unexpected given the restrictions imposed on routine clinical visits at ophthalmic clinics due to the COVID-19 pandemic.

Combined Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) with Ab Interno Canaloplasty (ABiC) in Conjunction with Phacoemulsification for the Treatment of POAG

In a prospective, interventional, non-comparative, case-series study, Al Habash and colleagues (2020) reported the surgical outcomes of combined gonioscopy-assisted transluminal trabeculotomy (GATT) with ab interno canaloplasty (ABiC) in conjunction with phacoemulsification for the treatment of patients with POAG. This trial included POAG patients who underwent combined GATT and ABiC in conjunction with phacoemulsification performed between January 2018 and August 2018. Main outcome measures include surgical success rate, changes in IOP, number of anti-glaucoma medications, corrected distance visual acuity (CDVA), and complications. These researchers enrolled 19 patients (20 eyes) in this study. The mean age was 61.2 ± 6 years, and all the patients completed a 12-month follow-up. The overall success rate was 100 %. The mean baseline IOP was 19.75 ± 4.68 mmHg, and at 12 months, the mean IOP was 13.30 ± 1.30 mmHg (IOP reduction of 32.7 %). The baseline number of anti-glaucoma medications was 3.4 ± 0.6 (range of 2 to 4 medications), and after 12 months follow-up, the number was reduced to 1.1 ± 1.0 (range of 0 to 2 medications). The CDVA for all 20 eyes was 0.85 ± 0.58 LogMAR at baseline, and 0.16 ± 0.30 LogMAR at 12-month follow-up. Only 6 eyes developed hyphema, which had cleared by the 1st post-operative month, and 3 eyes needed medical treatment for post-operative IOP spikes. The authors concluded that this study, to their knowledge, was the 1st to report on the outcomes of combined GATT with ABiC in conjunction with phacoemulsification for POAG. According to the 12-month results of this trial, the combined procedure appeared to be safe and effective in decreasing the IOP and the number of anti-glaucoma medications in POAG patients. These researchers stated that the drawbacks of this study included the limited number of patients (n = 19) and the lack of long follow-up duration. Furthermore, it was a non-randomized study with no control group. Despite these drawbacks, these investigators believed that combined GATT with ABiC in conjunction with phacoemulsification has the potential to be a great alternative option for the management of POAG, given the favorable efficacy outcomes and high safety profile in all eyes in this study. These researchers recommended that more extensive RCTs be carried out with a longer follow-up in order to examine the long-term outcomes of this procedure in such patient population.

Ab Interno Canaloplasty for the Treatment of Primary Open-Angle Glaucoma

In a single-center, case-series study, Korber (2018) examined the effectiveness of ab interno canaloplasty (ABiC) in patients with POAG. This trial included patients with cataract and open-angle glaucoma (combined procedure) and pseudophakic patients (mean age of 76 years; range of 66 to 83 years) with POAG who underwent ABiC using the iTrack 250-μm micro-catheter to circumferentially visco-dilate and intubate Schlemm’s canal without placement of a tensioning suture. The primary endpoints were mean IOP and mean number of glaucoma medications at 1, 3, 6, 9, and 12 months post-operatively. A total of 20 patients (20 eyes) were enrolled in this trial. Mean IOP reduced from 18.5 ± 3.44 mm Hg pre-operatively to 14.88 ± 2.82 mm Hg (n = 17), 13.80 ± 2.05 (n = 12), 14.57 ± 2.59 mm Hg (n = 9) and 15.47 ± 2.42 (n = 6) at 1, 3, 6 and 9 months post-operatively. The 12‑month data for 2 patients showed that IOP had reduced from 17 mm Hg pre-operatively to 16 mm Hg in 1 patient and from 20 mm Hg to 13 mm Hg in the other patient. The mean number of medications was reduced from 2.4 pre-operatively to 0.25 at the last follow-up visit. There was 1 reported complication of limited descemetolysis near the limbus by the viscoelastic during the dilatation of Schlemm’s canal. No AEs as a result of the device were reported. The authors concluded that ABiC was straight-forward to perform in this group of patients with minimal complications. Moreover, these researchers stated that although the initial findings from this study showed that ABiC was comparable to conventional canaloplasty in lowering IOP and medication dependency, long-term follow-up in a large patient cohort is needed to confirm the effectiveness of this minimally invasive glaucoma procedure. The authors noted that the drawbacks of this trial included the small study cohort (n = 20); and follow-up data beyond 6 months post-operative were only available for a handful of patients.

Gillmann and Mansouri (2020) noted that the past 10 years has witnessed an unprecedented growth in therapeutic options of glaucoma via the introduction of (MIGS. In a systematic review and meta-analysis, these investigators provided an understanding of the currently available MIGS and examined what data are currently available to guide treatment choice. Out of 2,567 studies identified, a total of 77 were retained for analysis, including 28 comparative studies, and 12 RCTs. Overall, 7,570 eyes were included. When data permitted, the weighted mean difference (WMD) in IOP reduction was calculated for comparison purposes. Weighted mean IOP reductions from all analyzed studies were: 15.3 % (iStent), 29.1 % (iStent inject), 36.2 % (ab interno canaloplasty), 34.4 % (Hydrus), 36.5 % (gonioscopically-assisted transluminal trabeculotomy), 24.0 % (trabectome), 25.1 % (Kahook dual blade), 30.2 % (Cypass), 38.8 % (XEN), and 50.0 % (Preserflo). The authors concluded that one of the advantages of the heterogenous range of available MIGS options is the chance to tailor therapy in an individualized manner; however, high-quality data are needed to make this choice more than an educated guess. Overall, this review confirmed the effectiveness of assessed MIGS compared with stand-alone phacoemulsification; however, it highlighted that only few studies compared different MIGS techniques and even fewer evaluated MIGS against criterion standard treatments. These researchers stated that current evidence, while non-negligible, is mostly limited to heterogenous non-randomized studies and uncontrolled, retrospective comparisons, with few quality RCTs. This resulted in significant variability in studies ’ results and a blurring of the outcomes, and further highlighted the need for carefully designed RCTs. These investigators suggested that future research should be comparative and include relevant comparators, standardized to report key outcome features, long-term follow-up to examine sustainability and late complications.

Balas and Mathew (2023) stated that MIGS has emerged as a novel approach in the therapeutic options for glaucoma, offering a range of diverse procedures and devices aimed at reducing IOP. MIGS can be broadly classified into several categories: those that enhance trabecular out-flow (Trabectome, iStent, Hydrus Microstent, Kahook Dual Blade, high-frequency deep sclerotomy, and gonioscopy-assisted transluminal trabeculotomy), those that augment supra-choroidal out-flow (CyPass Microstent and iStent Supra), those that target Schlemm's canal (TRAB360 and the OMNI Surgical System, Streamline, and ab interno canaloplasty), and conjunctival bleb-forming procedures (EX-PRESS Glaucoma Filtration Device, Xen Gel Stent and PreserFlo MicroShunt). MIGS is considered to have a shorter surgical time and fewer severe complications when compared to traditional glaucoma surgeries such as trabeculectomy and glaucoma drainage device implantation (Ahmed, Baerveldt, and Molteno valves). These investigators examined the distinct MIGS devices and procedures, their underlying mechanisms, and clinical outcomes, emphasizing the importance of evaluating the effectiveness and complications of each approach individually. The authors concluded that as the field of MIGS continues to evolve, it is important to prioritize high-quality, long-term studies to better understand the safety and effectiveness of these innovative interventions in glaucoma management.

Kicinska and Mare (2023) reported the 3-year results of a prospective assessment of 3 modifications of canaloplasty (C): ab externo (ABeC), mini-canaloplasty (miniABeC), and ab interno (ABiC) carried out concomitantly with cataract removal in patients with POAG. A total of 48 patients were randomized for one of the surgeries: ABeC, miniABeC, or ABiC and cataract removal -- 16 eyes for each group. Follow-up examinations were performed on the day of the surgery, on days 1 and 7, after 1, 3, 6 months, and at 1, 2, and 3 years. Complete and qualified success was an IOP of 15 mmHg or less without or with anti-glaucoma eye-drops, respectively. The IOP reduction of 20 % or more was considered an additional success criterion. Within 3 years the probability of qualified success was ABiC and miniABeC – 94 %, ABeC – 100 %, and of complete success ABiC – 75 %, miniABeC – 100 %. At the 3-year follow-up, the median IOP decreased from 22 to 15 mmHg in the ABeC group (p = 0.001), from 22 to 15 mmHg in the miniABeC group 15 (p < 0.001), and from 21 to 15 mmHg in the ABiC group (p = 0.001) compared to the post-washout stage. The IOP dropped by 20 % or more without medications in 56.2 % of patients post-ABiC, 68.8 % post-miniABeC, and 75 % post-ABeC. median number of anti-glaucoma medications dropped in all 3 groups; at the 3-year follow-up, only 1 patient following ABeC, and 4 patients following miniABeC needed treatment; and 1 patient required re-operation and further intensification of topical treatment-post miniABeC. The levels of IOP, CDVA, and success probability at the 36-month follow-up showed no significant difference for individual groups. The authors concluded that after 36 months of observation, all 3 variants were effective in decreasing IOP and medication numbers, with no late complications. The results showed no significant differences while comparing the groups. Among patients after ABiC, a few needed medications; perhaps further observation on larger groups would enhance differences in medicated and un-medicated IOP reduction. These researchers noted that all 3 modifications combined with phacoemulsification could be considered as adequate for individuals with POAG at a mild-to-moderate stage with vision-impairing cataract and no history of trauma to iridocorneal angle, and under the assumption of a patent out-flow system. Moreover, these investigators stated that it needs to be emphasized that this trial was of a preliminary nature and has to be validated with more data from multi-center studies.

The authors stated that the findings of this study should be treated as preliminary in their nature. This trial had several drawbacks, namely, a relatively small sample size (n = 48) and a short observation period. The scarce number of enrollees requires interpreting these results with great caution. In this study, all modifications of C (ABeC, miniABeC, and ABiC) carried out with phacoemulsification gave a satisfactory lowering of IOP, a significant reduction in the number of medications, and an improvement of CDVA as well as visual field (VF) stabilization without complications in Caucasians suffering from mild-to-moderate POAG. Two and three years post-operatively, no differences in median IOP reduction, achieved CDVA, or surgical success were noted. The only complication registered was posterior capsule opacification (PCO), which was rather a consequence of the phacoemulsification procedure and was easily removable. The findings of this study were in line with previously published data on phacoC and initial results of miniABeC. This study also added to the state of the literature on ABiC. Three years after surgery, a few post-ABiC patients needed re-introduction of topical treatment. These investigators stated that further research on a larger sample is needed to confirm this tendency. Perhaps ABiC would be more suitable for patients who are compliant to the use of eye-drops.

A StatPearls’ review on “Minimally invasive glaucoma surgery” (Gurnani and Tripathy, 2023) stated that MIGS has revolutionized glaucoma management over the past few years. It is a relatively new modality of glaucoma management that is gaining popularity as large numbers of surgeons are opting for it. The post-operative outcomes and patient satisfaction rate are good with these procedures. The safety profile and efficacy are also good. The authors stated that MIGS has opened a new door for mild-to-moderate glaucoma management, reducing the medication burden on the patients. Recent studies have provided highly encouraging results, and more large-scale studies with long-term follow-up are needed to provide better insight and understanding of MIGS.

Cheema and Cheema (2024) examined the evolution, current status, and future potential of MIGS, which offer a less invasive alternative to traditional glaucoma surgeries, primarily aimed at reducing IOP, minimizing tissue trauma, and providing a safer profile. With the emergence of devices such as the Trabectome, iStent, and others, MIGS have expanded the surgical armamentarium, allowing personalized, patient-centered care. Despite their advantages, MIGS face challenges such as effectiveness in severe cases, long-term data, and accessibility. The learning curve and the necessity for precise patient selection highlight the need for thorough training in MIGS techniques. The authors stated that ongoing research and technological innovations continue to refine MIGS capabilities and applications, promising to further transform glaucoma management and patient outcomes.

In a retrospective, single-center, consecutive case-series study, Koerber and Ondrejka (2024) examined the long-term effectiveness of iTrack ab-interno canaloplasty for reducing IOP and the number of glaucoma medications in patients with POAG and pseudo-exfoliative glaucoma. Subjects were treated with either ab-interno canaloplasty performed as a stand-alone procedure or combined with cataract surgery and were followed for up to 6 years. iTrack was used to circumferentially catheterize and visco-dilate the Schlemm canal over 360 degrees. Primary effectiveness endpoints included IOP and number of glaucoma medications at 12, 24, 36, 48, 60, and 72 months after surgery. A total of 27 eyes of 22 patients, with a mean age of 76.9 ± 6.3 years, were recruited. Mean IOP was reduced significantly from 19.9 ± 5.2 mm Hg (n = 27) at baseline (no wash-out) to 14.6 ± 3.3 mm Hg at the 6-year follow-up (n = 18; p < 0.001). The number of medications was significantly reduced from 1.9 ± 1 at baseline to 0.9 ± 0.9 at 6 years (n = 18; p = 0.005). At all time-points, there was no statistical difference between POAG (n = 16) and pseudo-exfoliative (n = 11) eyes, nor between stand-alone procedures (n = 4) and those combined with phacoemulsification (n = 23). At 72 months, the mean reduction in IOP was 27 % while 53 % in the number of medications. No serious complications were recorded. The authors concluded that this trial reported a clinically and statistically significant reduction in IOP and number of medications achieved by ab-interno canaloplasty using the iTrack canaloplasty micro-catheter and that these reductions were sustained up to 6 years post-operatively. In addition, these reductions appeared comparable with other MIGS devices. These researchers stated that MIGS appeared to provide long-term sustained effectiveness; however, further studies are needed to confirm the long-term outcomes when canaloplasty is performed in association with cataract removal or as a stand-alone procedure.

The authors stated that the key drawbacks of this study were associated with the retrospective, single-center design, such as the small number of eyes (n = 27), selection bias, the heterogenous nature of the cohort, and loss of follow-up, which is sometimes linked to the elderly nature of the patients.

References

The above policy is based on the following references:

Aktas Z, Tian B, McDonald J, et al. Application of canaloplasty in glaucoma gene therapy: Where are we? J Ocul Pharmacol Ther. 2014;30(2-3):277-282.
Al Habash A, Alrushoud M, Al Abdulsalam O, et al. Combined gonioscopy-assisted transluminal trabeculotomy (GATT) with Ab interno canaloplasty (ABiC) in cnjunction with phacoemulsification: 12-month outcomes. Clin Ophthalmol. 2020;14:2491-2496.
American Academy of Ophthalmology (AAO). Primary open-angle glaucoma. Preferred Practice Pattern. San Francisco, CA: AAO; 2005.
American Academy of Ophthalmology Glaucoma Panel. Primary open-angle glaucoma. Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 2010; 2015; 2016.
Armstrong JJ, Wasiuta T, Kiatos E, et al. The effects of phacoemulsification on intraocular pressure and topical medication use in patients with glaucoma: A systematic review and meta-analysis of 3-year data. J Glaucoma. 2017;26(6):511-522.
Ayyala RS, Chaudhry AL, Okogbaa CB, Zurakowski D. Comparison of surgical outcomes between canaloplasty and trabeculectomy at 12 months' follow-up. Ophthalmology. 2011;118:2427-2433.
Balas M, Mathew DJ. Minimally invasive glaucoma surgery: A review of the literature. Vision (Basel). 2023;7(3):54.
Brown RH, Tsegaw S, Dhamdhere K, Lynch MG. Viscodilation of Schlemm canal and trabeculotomy combined with cataract surgery for reducing intraocular pressure in open-angle glaucoma. J Cataract Refract Surg. 2020;46(4):644-645.
Brusini P, Tosoni C, Zeppieri M. Canaloplasty in corticosteroid-induced glaucoma. Preliminary results. J Clin Med. 2018;7(2).
Brusini P, Tosoni C. Canaloplasty after failed trabeculectomy: A possible option. J Glaucoma. 2014;23(1):33-34.
Brusini P. Canaloplasty in open-angle glaucoma surgery: A four-year follow-up. ScientificWorldJournal. 2014;2014:469609.
Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2004;(2):CD004399.
Carassa RG, Bettin P, Fiori M, Brancato R. Viscocanalostomy versus trabeculectomy in white adults affected by open-angle glaucoma: A 2-year randomized, controlled trial. Ophthalmology. 2003;110(5):882-887.
Carassa RG, Bettin P, Fiori M, et al. Viscocanalostomy: A pilot study. Eur J Ophthalmol. 1998;8:57-61.
Chai C, Loon SC. Meta-analysis of viscocanalostomy versus trabeculectomy in uncontrolled glaucoma. J Glaucoma. 2010;19(8):519-527.
Chakib A, Ouarrach N, Haloui M, et al. Viscocanalostomy: Preliminary clinical results. J Fr Ophtalmol. 2010;33(6):403-407.
Cheema AA, Cheema HR. The evolution and current landscape of minimally invasive glaucoma surgeries: A review. 2024;16(1):e52183.
Davids A-M, Pahlitzsch M, Boeker A, et al. Ab interno canaloplasty (ABiC) -- 12-month results of a new minimally invasive glaucoma surgery (MIGS). Graefes Arch Clin Exp Ophthalmol. 2019;257(9):1947-1953.
Dickerson JE, Jr., Harvey AE, Brown RH. Ab interno canaloplasty and trabeculotomy outcomes for mild, moderate, and advanced open-angle glaucoma: A ROMEO analysis. Clin Ophthalmol. 2024;18:1433-1440.
El Salloukh A, Ansari AS, Chiu A, Mathews D. Evaluating the long-term efficacy and effectiveness of viscocanalostomy and combined phacoemulsification with viscocanalostomy in the treatment of patients with uveitic glaucoma: 5-year follow up data. BMC Surg. 2021;21(1):200.
Eldaly MA, Bunce C, Elsheikha OZ, Wormald R. Non-penetrating filtration surgery versus trabeculectomy for open-angle glaucoma. Cochrane Database Syst Rev. 2014;2:CD007059.
Francis BA, Singh K, Lin SC, et al. Novel glaucoma procedures: A report by the American Academy of Ophthalmology. Ophthalmology. 2011;118(7):1466-1480.
Gabai A, Cimarosti R, Battistella C, et al. Efficacy and safety of trabeculectomy versus nonpenetrating surgeries in open-angle glaucoma: A meta-analysis. J Glaucoma. 2019;28(9):823-833.
Gad AAM, Abdulhalim BH, Lotfy A, et al. Combined phacoemulsification and viscocanalostomy with Ologen implant versus combined phacoemulsification and viscocanalostomy. BMC Ophthalmol. 2019 Feb 6;19(1):45.
Gallardo MJ, Dhamdhere K, Dickerson JE, Jr. Canaloplasty and trabeculotomy ab interno combined with cataract surgery: 12-month outcomes in Hispanic patients with open-angle glaucoma. Clin Ophthalmol. 2022a;16:905-908.
Gallardo MJ, Pyfer MF, Vold SD, et al; on behalf of the GEMINI study group. Canaloplasty and trabeculotomy combined with phacoemulsification for glaucoma: 12-month results of the GEMINI Study. Clin Ophthalmol. 2022b;16:1225-1234.
Gallardo MJ, Sarkisian SR, Jr, Vold SD, et al. Canaloplasty and trabeculotomy combined with phacoemulsification in open-angle glaucoma: Interim results from the GEMINI Study. Clin Ophthalmol. 2021;15:481-489.
Ghate D, Wang X. Surgical interventions for primary congenital glaucoma. Cochrane Database Syst Rev. 2015;1:CD008213.
Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: Where is the evidence? Asia Pac J Ophthalmol (Phila). 2020;9(3):203-214.
Gilmour DF, Manners TD, Devonport H, et al. Viscocanalostomy versus trabeculectomy for primary open angle glaucoma: 4-year prospective randomized clinical trial. Eye. 2007;1-6.
Gimbel HV, Penno EE, Ferensowicz M. Combined cataract surgery, intraocular lens implantation, and viscocanalostomy. J Cataract Refract Surg. 1999;25(10):1370-1375.
Godfrey et al, Canal surgery in adult glaucomas. Curr Opin Ophthalmol. 2009;20:116- 121.
Goldberg L. Canaloplasty: A promising new extension to non-penetrating surgery. Opthalmol Manage. 2006 Mar.
Grabska-Liberek I, Duda P, Rogowska M, et al. 12-month interim results of a prospective study of patients with mild to moderate open-angle glaucoma undergoing combined viscodilation of Schlemm's canal and collector channels and 360° trabeculotomy as a standalone procedure or combined with cataract surgery. Eur J Ophthalmol. 2022;32(1):309-315.
Grieshaber MC, Fraenkl S, Schoetzau A, et al. Circumferential viscocanalostomy and suture canal distension (canaloplasty) for whites with open-angle glaucoma. J Glaucoma. 2011;20(5):298-302.
Grieshaber MC, Schoetzau A, Grieshaber HR, Stegmann R. Canaloplasty with Stegmann Canal Expander for primary open-angle glaucoma: Two-year clinical results. Acta Ophthalmol. 2017;95(5):503-508.
Grieshaber MC. Stegmann Canal Expander for canaloplasty: A novel technique. Eur J Ophthalmol. 2018;28(4):472-478.
Gurnani B, Tripathy K. Minimally invasive glaucoma surgery. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; updated August 25, 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK582156/. Accessed: March 19, 2024.
Hasanov JV, Kasimov EM. Late results of phaco-canaloplasty in patients with concomitant advanced pseudoexfoliation glaucoma and cataract. Vestn Oftalmol. 2018;134(3):28-34.
Henahan JF. Combined viscocanalostomy-phacoemulsification achieves significant IOP reductions Canadian study indicates. Cataract Refract Surg EuroTimes. 1998 Jul-Aug. (quoting H.V. Gimbel, M.D., Gimbel Eye Centre, Calgary, AB). Available at: http://www.escrs.ie/pubs/euro/v3i4/etv3i4b1.html. Accessed December 13, 1999.
Hirsch L, Cotliar J, Vold S, et al. Canaloplasty and trabeculotomy ab interno with the OMNI System combined with cataract surgery in open-angle glaucoma: 12-month outcomes from the ROMEO Study. J Cataract Refract Surg. 2021;47(7):907-915.
Ho DK, Garrick A, Aazem S, Mathews D. Effect of primary phacoviscocanalostomy/ viscocanalostomy on intraocular pressure of normal tension glaucoma patients: 3-year results. BMC Ophthalmol. 2017;17(1):201.
Hondur A, Onol M, Hasanreisoglu B. Nonpenetrating glaucoma surgery: Meta-analysis of recent results. J Glaucoma. 2008;17(2):139-146.
Hughes T, Traynor M. Clinical results of ab interno canaloplasty in patients with open-angle glaucoma. Clin Ophthalmol. 2020;14:3641-3650.
Jacobs DS. Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed March 2021.
Jacobs DS. Open-angle glaucoma: Treatment. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed March 2014; February 2016; February 2019; February 2021.
Jonescu-Cuypers C, Jacobi P, Konen W, et al. Primary viscocanalostomy versus trabeculectomy in white patients with open-angle glaucoma: A randomized clinical trial. Ophthalmology. 2001;108(2):254-258.
Kicinska AK, Mare Rekas M. Safety and efficacy of three modifications of canaloplasty to treat open-angle glaucoma: 3-year outcomes. J Clin Med. 2023;12(20):6475.
Klabe K, Kaymak H. Standalone trabeculotomy and viscodilation of Schlemm's canal and collector channels in open-angle glaucoma using the OMNI Surgical System: 24-month outcomes. Clin Ophthalmol. 2021;15:3121-3129.
Kobayashi H, Kobayashi K, Okinami S. A comparison of the intraocular pressure-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C in bilateral open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2003;241(5):359-366.
Kobayashi H, Kobayashi K. Randomized comparison of the intraocular pressure-lowering effect of phacoviscocanalostomy and phacotrabeculectomy. Ophthalmology. 2007;114(5):909-914.
Kodomskoi L, Kotliar K, Schroder AC, et al. Suture-probe canaloplasty as an alternative to canaloplasty using the iTrack microcatheter. J Glaucoma. 2019;28(9):811-817.
Koerber N. Canaloplasty - a new approach to nonpenetrating glaucoma surgery. Techniques in Ophthalmol. 2007;5(3):102-106.
Koerber N. Canaloplasty in one eye compared with viscocanalostomy in the contralateral eye in patients with bilateral open-angle glaucoma. J Glaucoma. 2012;21(2):129-134.
Koerber N, Ondrejka S. 6-year efficacy and safety of iTrack ab-interno canaloplasty as a stand-alone procedure and combined with cataract surgery in primary open angle and pseudoexfoliative glaucoma. J Glaucoma. 2024;33(3):176-182.
Korber N. Ab interno canaloplasty for the treatment of glaucoma: A case series study. Spektrum Augenheilkd. 2018;32(6):223-227.
Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: Circumferential viscodilation and tensioning of Schlemm's canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: Interim clinical study analysis. J Cataract Refract Surg. 2007;33(7):1217-1226.
Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: Circumferential viscodilation and tensioning of Schlemm canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: Two-year interim clinical study results. J Cataract Refract Surg. 2009;35(5):814-824.
Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: Three-year results of circumferential viscodilation and tensioning of Schlemm canal using a microcatheter to treat open-angle glaucoma. J Cataract Refract Surg. 2011;37:682-690.
Lewis RA. Canaloplasty: The next step in the glaucoma surgery evolution. Ophthalmol Times Eur. 2006 Jan 1.
Liang Y, Yu Q, Ji F, et al. Viscocanalostomy combined with nearly 360-degree suture trabeculotomy for the treatment of primary congenital glaucoma: A preliminary report of a novel technique for trabeculotomy. Graefes Arch Clin Exp Ophthalmol. 2020;258(2):379-386.
Lin ZJ, Xu S, Huang SY, et al. Comparison of canaloplasty and trabeculectomy for open angle glaucoma: A meta-analysis. Int J Ophthalmol. 2016;9(12):1814-1819.
Liu H, Zhang H, Li Y, Yu H. Safety and efficacy of canaloplasty versus trabeculectomy in treatment of glaucoma. Oncotarget. 2017;8(27):44811-44818.
Lommatzsch C, Heinz C, Heiligenhaus A, Koch JM. Canaloplasty in patients with uveitic glaucoma: A pilot study. Graefes Arch Clin Exp Ophthalmol. 2016;254(7):1325-1330.
Lopes-Cardoso I, Esteves F, Amorim M, et al. Circumferential viscocanalostomy with suture tensioning in Schlemm canal (canaloplasty)-one year experience. Arch Soc Esp Oftalmol. 2013;88(6):207-215.
Luke C, Dietlein TS, Jacobi PC, A prospective randomized trial of viscocanalostomy versus trabeculectomy in open-angle glaucoma: A 1-year follow-up study. J Glaucoma. 2002;11(4):294-299.
Matlach J, Klink T. Trabeculectomy versus canaloplasty. Ophthalmologe. 2015;112(4):325-331.
Mendrinos E, Mermoud A, Shaarawy T. Nonpenetrating glaucoma surgery. Surv Ophthalmol. 2008;53(6):592-630.
Minckler DS, Hill RA. Use of novel devices for control of intraocular pressure. Exp Eye Res. 2009;88(4):792-798.
Moradian K, Daneshvar R, Saffarian L, et al. The efficacy of viscocanalostomy for uncontrollable primary open-angle glaucoma in a developing country. Indian J Ophthalmol. 2013;61(2):71-73.
Murphy JT, III, Terveen DC, Aminlari AE, et al. A multicenter 12-month retrospective evaluation of canaloplasty and trabeculotomy in patients with open-angle glaucoma: The ROMEO 2 Study. Clin Ophthalmol. 2022;16:3043-3052.
National Collaborating Centre for Acute Care. Glaucoma. Diagnosis and management of chronic open angle glaucoma and ocular hypertension. Methods, Evidence, and Guidance. London, UK: National Collaborating Centre for Acute Care; April 2009.
National Institute for Health and Clinical Excellence (NICE). Ab interno canaloplasty for open-angle glaucoma. Interventional procedures guidance. Published: November 22, 2022. Available at: https://www.nice.org.uk. Accessed May 22, 2024.
National Institute for Health and Clinical Excellence (NICE). Canaloplasty for open-angle glaucoma. Interventional Procedure Guidance 260. London, UK: NICE; May 2008.
Netland PA; Ophthalmic Technology Assessment Committee Glaucoma Panel, American Academy of Ophthalmology. Nonpenetrating glaucoma surgery. Ophthalmology. 2001;108(2):416-421.
O'Brart DP, Shiew M, Edmunds B. A randomised, prospective study comparing trabeculectomy with viscocanalostomy with adjunctive antimetabolite usage for the management of open angle glaucoma uncontrolled by medical therapy. Br J Ophthalmol. 2004;88(8):1012-1017.
Obstbaum SA. New approaches to trabecular surgery. J Cataract Refract Surg. 1999;25(3):297.
Ondrejka S, Korber N, Dhamdhere K. Long-term effect of canaloplasty on intraocular pressure and use of intraocular pressure-lowering medications in patients with open-angle glaucoma. J Cataract Refract Surg. 2022;48(12):1388-1393.
Peckar CO, Korber N. Canaloplasty for open angle glaucoma: A three years critical evaluation and comparison with viscocanalostomy. Spektrum der Augenheilkunde. 2008;22(4):240-246.
Pyfer MF, Gallardo M, Campbell A, et al. Suppression of diurnal (9AM-4PM) IOP fluctuations with minimally invasive glaucoma surgery: An analysis of data from the prospective, multicenter, single-arm GEMINI Study. Clin Ophthalmol. 2021;15:3931-3938.
Qian CX, Zong Y, Chen Q, Yuan ZL. Viscocanalostomy combined with trabeculotomy and mitomycin C in the treatment of primary congenital glaucoma. Int J Ophthalmol. 2017;10(6):919-924.
Royal College of Ophthalmologists, Scientific Department. Guidelines for the management of open-angle glaucoma and ocular hypertension. London, UK: RCO; 2004.
Seuthe A-M, Szurman P, Januschowski K. Canaloplasty with suprachoroidal drainage in patients with pseudoexfoliation glaucoma - Four years results. Curr Eye Res. 2021;46(2):217-223.
Shaarawy T, Nguyen C, Schnyder C, Mermoud A. Five year results of viscocanalostomy. Br J Ophthalmol. 2003;87(4):441-445.
Shingleton B, Tetz M, Korber N. Circumferential viscodilation and tensioning of Schlemm canal (canaloplasty) with temporal clear corneal phacoemulsification cataract surgery for open-angle glaucoma and visually significant cataract: One-year results. J Cataract Refract Surg. 2008;34(3):433-440.
Smit BA, Johnstone MA. Effects of viscoelastic injection into Schlemm's canal in primate and human eyes: Potential relevance to viscocanalostomy. Ophthalmology. 2002;109(4):786-792.
Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316-322.
Sun P, Liu H-W, Zhou P-P, Meng Y. Canaloplasty for the treatment of primary open-angle glaucoma: A protocol of systematic review and meta-analysis. Medicine (Baltimore). 2020;99(22):e20408.
Tan YL, Chua J, Ho CL. Updates on the surgical management of pediatric glaucoma. Asia Pac J Ophthalmol (Phila). 2016;5(1):85-92.
Thederan L, Grehn F, Klink T. Comparison of canaloplasty with trabeculectomy. Klin Monbl Augenheilkd. 2014;231(3):256-261.
Tian B, Kaufman PL. A potential application of canaloplasty in glaucoma gene therapy. Transl Vis Sci Technol. 2013;2(1). pii: 2.
Toneatto G, Zeppieri M, Papa V, et al. 360° ab-interno Schlemm's canal viscodilation with OMNI viscosurgical systems for open-angle glaucoma -- midterm results. J Clin Med. 2022;11(1):259.
U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). iScience Surgical Corporation Ophthalmic Microcannula. Summary of Safety and Effectiveness. 510(k) No. K041108. Rockville, MD: FDA; June 22, 2004.
Vass C, Menapace R. Surgical strategies in patients with combined cataract and glaucoma. Curr Opin Ophthalmol. 2004;15(1):61-66.
Verges C, Cazal J, Lavin C. Surgical strategies in patients with cataract and glaucoma. Curr Opin Ophthalmol. 2005;16(1):44-52.
Wagdy FM. Canaloplasty versus viscocanalostomy in primary open angle glaucoma. Electron Physician. 2017;9(1):3665-3671.
Wild GJ, Kent AR, Peng Q. Dilation of Schlemm's canal in viscocanalostomy: Comparison of 2 viscoelastic substances. J Cataract Refract Surg. 2001;27(8):1294-1297.
Williamson BK, Vold SD, Campbell A, et al. Canaloplasty and trabeculotomy with the OMNI System in patients with open-angle glaucoma: Two-year results from the ROMEO Study. Clin Ophthalmology. 2023:17:1057-1066.
Yalvac IS, Sahin M, Eksioglu U, et al. Primary viscocanalostomy versus trabeculectomy for primary open-angle glaucoma: Three-year prospective randomized clinical trial. J Cataract Refract Surg. 2004;30(10):2050-2057.
Yarangumeli A, Koz OG, Alp MN, et al. Viscocanalostomy with mitomycin-C: A preliminary study. Eur J Ophthalmol. 2005;15(2):202-208.
Zhang B, Kang J, Chen X. A system review and meta-analysis of canaloplasty outcomes in glaucoma treatment in comparison with trabeculectomy. J Ophthalmol. 2017;2017:2723761.

Last Review 07/10/2024

Effective: 06/22/2000

Next Review: 05/08/2025
Review History
Definitions

Viscocanalostomy and Canaloplasty

Table Of Contents

Policy

Scope of Policy

Medical Necessity

Experimental, Investigational, or Unproven

CPT Codes / HCPCS Codes / ICD-10 Codes

CPT codes covered if selection criteria are met:

CPT codes not covered for indications listed in the CPB:

ICD-10 codes covered if selection critreria are met:

ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):

Combined phacoemulsification and viscocanalostomy with Ologen implant:

CPT codes not covered for indications listed in the CPB:

Viscocanalostomy with Ologen implant - no specific code:

ICD-10 codes not covered for indications listed in the CPB:

Canaloplasty and trabeculotomy ab interno with the OMNI System combined with cataract surgery:

CPT codes not covered for indications listed in the CPB:

Other CPT codes related to the CPB:

HCPCS codes not covered for indications listed in the CPB:

ICD-10 codes not covered for indications listed in the CPB:

Combined gonioscopy-assisted transluminal trabeculotomy (GATT) with ab interno canaloplasty (ABiC) in conjunction with phacoemulsification:

CPT codes not covered for indications listed in the CPB:

Other CPT codes related to the CPB:

ICD-10 codes not covered for indications listed in the CPB:

Background

Canaloplasty for the Treatment of Uveitic Glaucoma

Canaloplasty for the Treatment of Normal-Tension Glaucoma

Viscocanalostomy / Phacoviscocanalostomy for the Treatment of Glaucoma

Viscocanalostomy and Combined Phacoemulsification with Viscocanalostomy in the Treatment of Uveitic Glaucoma

Corticosteroid-Induced Glaucoma

Stegmann Canal Expander for Canaloplasty

Combined Phacoemulsification and Viscocanalostomy with Ologen Implant

Ab Interno Canaloplasty (ABiC)

Canaloplasty for the Treatment of Pseudo-Exfoliation Glaucoma

Canaloplasty and Trabeculotomy Ab Interno with the OMNI System Combined with Cataract Surgery for the Treatment of POAG

Combined Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) with Ab Interno Canaloplasty (ABiC) in Conjunction with Phacoemulsification for the Treatment of POAG

Ab Interno Canaloplasty for the Treatment of Primary Open-Angle Glaucoma

References

Policy History

Additional Information